menu
    • menu
    [{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Mundipharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Mundipharma"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rezafungin","moa":"Candida","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Melinta Therapeutics"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"Scynexis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-beta-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"RHB-204","moa":"50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"Rediscovery Life Sciences","sponsor":"PaxMedica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rediscovery Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rediscovery Life Sciences \/ PaxMedica","highestDevelopmentStatusID":"10","companyTruncated":"Rediscovery Life Sciences \/ PaxMedica"},{"orgOrder":0,"company":"PaxMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Suramin","moa":"Acidic fibroblast growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PaxMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PaxMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PaxMedica \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs"},{"orgOrder":0,"company":"Biophore India Pharmaceuticals Pvt Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophore India Pharmaceuticals Pvt Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biophore India Pharmaceuticals Pvt Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophore India Pharmaceuticals Pvt Ltd \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Cantex Pharmaceuticals","sponsor":"Michigan Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cantex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cantex Pharmaceuticals \/ Michigan Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cantex Pharmaceuticals \/ Michigan Medicine"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1||Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"AGTR1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vicore Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hempstreet","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Partnership","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hempstreet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Hempstreet \/ MGC Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hempstreet \/ MGC Pharmaceuticals"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Albendazole monooxygenase (CYP3A4)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"MGC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MGC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Blessing Corporate Services","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin||Leukocyte elastase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Blessing Corporate Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blessing Corporate Services \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Blessing Corporate Services \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Suvratoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Termination","leadProduct":"Suvratoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Aridis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tosatoxumab","moa":"Alpha-hemolysin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aridis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aridis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Hinova","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Enzalutamide","moa":"Androgen Receptor||AR","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Biology \/ Hinova","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Hinova"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Undisclosed"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Corpometria Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proxalutamide","moa":"||Androgen Receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Applied Biology \/ Corpometria Institute","highestDevelopmentStatusID":"10","companyTruncated":"Applied Biology \/ Corpometria Institute"},{"orgOrder":0,"company":"Shenyang Tonglian Medicines Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Carrimycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenyang Tonglian Medicines Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shenyang Tonglian Medicines Co.,Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Carrimycin","moa":"antibiotics (Streptomyces strains)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenyang Tonglian Medicines Co.,Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenyang Tonglian Medicines Co.,Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fosfomycin Sodium","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Meitheal Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Fosfomycin Sodium","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Nabriva Therapeutics \/ Meitheal Pharmaceuticals"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Drugs for Neglected Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Benznidazole","moa":"antiprotozoal substances (metronidazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Laboratorio Elea Phoenix \/ Drugs for Neglected Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorio Elea Phoenix \/ Drugs for Neglected Diseases"},{"orgOrder":0,"company":"Thrombosis Research Institute","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thrombosis Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Thrombosis Research Institute \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Thrombosis Research Institute \/ Sanofi"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Manitoba \/ Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI","highestDevelopmentStatusID":"10","companyTruncated":"University of Manitoba \/ Canadian Institutes of Health Research | Research Manitoba | Ozmosis Research | CanVECTOR Network | Canadian Critical Care Trials Group | AVANTI"},{"orgOrder":0,"company":"Centro Medico del Noroeste","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centro Medico del Noroeste","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centro Medico del Noroeste \/ Alfasigma","highestDevelopmentStatusID":"10","companyTruncated":"Centro Medico del Noroeste \/ Alfasigma"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ingavirin","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"MSN Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MSN Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MSN Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MSN Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Optimus Pharma","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Optimus Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Optimus Pharma \/ JSS Medical Research","highestDevelopmentStatusID":"10","companyTruncated":"Optimus Pharma \/ JSS Medical Research"},{"orgOrder":0,"company":"The Medicines Patent Pool","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Medicines Patent Pool","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Medicines Patent Pool \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"The Medicines Patent Pool \/ Merck & Co"},{"orgOrder":0,"company":"Carbon Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carbon Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carbon Health \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Carbon Health \/ Merck & Co"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"CHIESI USA INC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CHIESI USA INC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"CHIESI USA INC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CHIESI USA INC \/ Undisclosed"},{"orgOrder":0,"company":"University of Kinshasa","sponsor":"European & Developing Countries Clinical Trials Partnership | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DEMOCRATIC REPUBLIC OF THE CONGO","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Kinshasa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Kinshasa \/ European & Developing Countries Clinical Trials Partnership | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"University of Kinshasa \/ European & Developing Countries Clinical Trials Partnership | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Oxford \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Waterbury Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Waterbury Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Waterbury Hospital"},{"orgOrder":0,"company":"UC San Francisco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UC San Francisco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UC San Francisco \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UC San Francisco \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Thomas M. Lietman","sponsor":"Bill & Melinda Gates Foundation | Pfizer Inc | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thomas M. Lietman","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thomas M. Lietman \/ Bill & Melinda Gates Foundation | Pfizer Inc | Stanford University","highestDevelopmentStatusID":"10","companyTruncated":"Thomas M. Lietman \/ Bill & Melinda Gates Foundation | Pfizer Inc | Stanford University"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"MicuRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Contezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MicuRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicuRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MicuRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Nafithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wockhardt \/ Jiangxi Jemincare Group Company","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Jiangxi Jemincare Group Company"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Paratek Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Paratek Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Public Offering","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Paromomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hetero Drugs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tedizolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Drugs","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hetero Drugs \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Drugs \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Zai Lab","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Zai Lab"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entasis Therapeutics","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Sulbactam","moa":"||Bacterial beta-lactamase TEM","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Entasis Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Entasis Therapeutics \/ Innoviva","highestDevelopmentStatusID":"10","companyTruncated":"Entasis Therapeutics \/ Innoviva"},{"orgOrder":0,"company":"Jeremy Burton","sponsor":"Archer Daniels Midland | London Health Sciences Centre Research Institute (Lawson) | St. Joseph's Health Care London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LH01-Myoviridae","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jeremy Burton","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jeremy Burton \/ Archer Daniels Midland | London Health Sciences Centre Research Institute (Lawson) | St. Joseph's Health Care London","highestDevelopmentStatusID":"10","companyTruncated":"Jeremy Burton \/ Archer Daniels Midland | London Health Sciences Centre Research Institute (Lawson) | St. Joseph's Health Care London"},{"orgOrder":0,"company":"Menarini","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Delafloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Menarini \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menarini \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"St George's, University of London | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ St George's, University of London | McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ St George's, University of London | McMaster University"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Aztreonam","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Wockhardt \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ Medpace, Inc"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meiji Seika Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"ICICI Prudential","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Wockhardt \/ ICICI Prudential","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ ICICI Prudential"},{"orgOrder":0,"company":"Allecra","sponsor":"Linical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allecra \/ Linical","highestDevelopmentStatusID":"10","companyTruncated":"Allecra \/ Linical"},{"orgOrder":0,"company":"Melinta Therapeutics","sponsor":"VenatoRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Melinta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Melinta Therapeutics \/ VenatoRx Pharmaceuticals"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Everest Medicines"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Menarini"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Everest Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Everest Medicines","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Everest Medicines"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Gardp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Gardp","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Gardp"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Melinta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Cefepime","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Melinta Therapeutics"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VenatoRx Pharmaceuticals \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ceftobiprole Medocaril","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"University of Queensland","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Queensland \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Queensland \/ Merck & Co"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evopoint Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evopoint Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Meropenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Public Offering","leadProduct":"Sulopenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sulopenem","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iterum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sulopenem Etzadroxil","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Iterum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iterum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iterum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ottawa Hospital Research Institute","sponsor":"Hamilton Health Sciences | The Ottawa Hospital | McMaster University | Sinai Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-1 adrenergic receptor | Beta-2 adrenergic receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ottawa Hospital Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ottawa Hospital Research Institute \/ Hamilton Health Sciences | The Ottawa Hospital | McMaster University | Sinai Health System","highestDevelopmentStatusID":"10","companyTruncated":"Ottawa Hospital Research Institute \/ Hamilton Health Sciences | The Ottawa Hospital | McMaster University | Sinai Health System"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Durlobactam","moa":"||Beta-lactamase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zai Lab \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zai Lab \/ Undisclosed"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Series C Financing","leadProduct":"Taniborbactam","moa":"||beta-lactamase inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VenatoRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"VenatoRx Pharmaceuticals \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"VenatoRx Pharmaceuticals \/ AMR Action Fund"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Enmetazobactam","moa":"||beta-lactamases","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Allecra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allecra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Enmetazobactam","moa":"||beta-lactamases","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Allecra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allecra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Allecra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MYR Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bulevirtide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MYR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MYR Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MYR Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bulevirtide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bulevirtide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bulevirtide","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bulevirtide Acetate","moa":"Bile acid transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis A Vaccine","moa":"B-lymphocytes","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Valneva \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Valneva \/ Deerfield Management Company","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Deerfield Management Company"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.31,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Valneva \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.31,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.31,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Financing","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.31,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Valneva","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Valneva"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Valneva","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Valneva"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA15","moa":"Borrelia outer surface protein A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Valneva","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Valneva"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Supreme Council of the Arab-African Economy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Supreme Council of the Arab-African Economy","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Supreme Council of the Arab-African Economy"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Staidson Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"BDB-001","moa":"C5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Staidson Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Staidson Biopharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rimegepant Sulfate","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"L-praziquantel","moa":"Calcium channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"R&G PharmaStudies Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ R&G PharmaStudies Co","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ R&G PharmaStudies Co"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Joincare Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Joincare Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Joincare Pharmaceutical"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Joincare Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Y.S.P. Industries M Sdn Bhd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TaiGen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TaiGen Biotechnology \/ Y.S.P. Industries M Sdn Bhd","highestDevelopmentStatusID":"10","companyTruncated":"TaiGen Biotechnology \/ Y.S.P. Industries M Sdn Bhd"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Undisclosed"},{"orgOrder":0,"company":"EmphyCorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EmphyCorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"EmphyCorp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EmphyCorp \/ Undisclosed"},{"orgOrder":0,"company":"Hunan Warrant Chiral Pharmaceutical","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hunan Warrant Chiral Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hunan Warrant Chiral Pharmaceutical \/ CytoDyn","highestDevelopmentStatusID":"10","companyTruncated":"Hunan Warrant Chiral Pharmaceutical \/ CytoDyn"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Amarex Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Amarex Clinical Research"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Highly Active Anti-Retroviral Therapy","moa":"||C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Novant Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Novant Health","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Novant Health"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Biomm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Biomm","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Biomm"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Macleods Pharmaceuticals Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Macleods Pharmaceuticals Limited","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Macleods Pharmaceuticals Limited"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Financing","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"||C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Financing","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"amfAR","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ amfAR","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ amfAR"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CytoDyn \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CytoDyn \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ CytoDyn","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Israelita Albert Einstein \/ CytoDyn"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ CytoDyn","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Israelita Albert Einstein \/ CytoDyn"},{"orgOrder":0,"company":"Biomm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biomm \/ Undisclosed"},{"orgOrder":0,"company":"HealthBioAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Maraviroc","moa":"||C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HealthBioAI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"HealthBioAI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HealthBioAI \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"MMV, EDCTP, WANECAM","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"KLU156","moa":"CD137 (4-1BB)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ MMV, EDCTP, WANECAM","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ MMV, EDCTP, WANECAM"},{"orgOrder":0,"company":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Meplazumab","moa":"CD147","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Meplazumab","moa":"CD147","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Meplazumab","moa":"CD147","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Meplazumab","moa":"CD147","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Meplazumab","moa":"CD147","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Pacific Meinuoke Bio Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Pacific Meinuoke Bio Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mupadolimab","moa":"CD73","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"The Cooper Health System","sponsor":"University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Cooper Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Cooper Health System \/ University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network","highestDevelopmentStatusID":"10","companyTruncated":"The Cooper Health System \/ University of California, Davis | Washington University School of Medicine | Baylor College of Medicine | Princeton Healthcare System | Cleveland Clinic | University of Georgia | St. Luke's University Health Network"},{"orgOrder":0,"company":"Zambon Group SpA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zambon Group SpA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Zambon Group SpA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zambon Group SpA \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Cholecystokinin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Cholecystokinin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Cholecystokinin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Proglumide","moa":"Cholecystokinin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Scinai Immunotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Proglumide","moa":"Cholecystokinin receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scinai Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scinai Immunotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scinai Immunotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Cambridge Biomedical Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cambridge Biomedical Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge Biomedical Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cambridge Biomedical Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Science Valley Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Science Valley Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Science Valley Research Institute \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Science Valley Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ravulizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine","moa":"Corynebacterium Mutated CRM197 (Cory mTOX)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine","moa":"Corynebacterium Mutated CRM197 (Cory mTOX)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Henan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine","moa":"Corynebacterium Mutated CRM197 (Cory mTOX)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Henan Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Henan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Pneumococcal 13-valent Conjugate Vaccine","moa":"Corynebacterium Mutated CRM197 (Cory mTOX)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Arpraziquantel","moa":"CYP11B1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Arpraziquantel","moa":"CYP11B1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"HLS Therapeutics \/ Amarin","highestDevelopmentStatusID":"10","companyTruncated":"HLS Therapeutics \/ Amarin"},{"orgOrder":0,"company":"Estudios Cl\u00ednicos Latino Am\u00e9rica","sponsor":"Amarin","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Estudios Cl\u00ednicos Latino Am\u00e9rica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Estudios Cl\u00ednicos Latino Am\u00e9rica \/ Amarin","highestDevelopmentStatusID":"10","companyTruncated":"Estudios Cl\u00ednicos Latino Am\u00e9rica \/ Amarin"},{"orgOrder":0,"company":"F2G Limited","sponsor":"IQVIA | Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ IQVIA | Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ IQVIA | Shionogi"},{"orgOrder":0,"company":"F2G Limited","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ AMR Action Fund"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Forbion","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Forbion"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Cowen"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Undisclosed"},{"orgOrder":0,"company":"F2G Limited","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F2G Limited","amount2":0.47999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.47999999999999998,"dosageForm":"Tablet","sponsorNew":"F2G Limited \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"F2G Limited \/ Shionogi"},{"orgOrder":0,"company":"MUHC Foundation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MUHC Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MUHC Foundation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MUHC Foundation \/ Undisclosed"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Mcgill University Health Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pulmonem \/ Mcgill University Health Centre","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Mcgill University Health Centre"},{"orgOrder":0,"company":"Pulmonem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmonem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pulmonem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pulmonem \/ Undisclosed"},{"orgOrder":0,"company":"University of Dundee","sponsor":"NHS Tayside | Insmed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Brensocatib","moa":"Dipeptidyl peptidase I","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Dundee","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Dundee \/ NHS Tayside | Insmed","highestDevelopmentStatusID":"10","companyTruncated":"University of Dundee \/ NHS Tayside | Insmed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DTaP-IPV Vaccine","moa":"Diphtheria toxoid\/Tetanus toxoid\/Pertussis toxin\/Poliovirus","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Clofazimine","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Mannkind \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mannkind \/ Undisclosed"},{"orgOrder":0,"company":"Generium","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Generium \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Undisclosed"},{"orgOrder":0,"company":"Imuneks Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Imuneks Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Imuneks Farma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Imuneks Farma \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Aurigene Pharmaceutical Services \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"The Global Antibiotic Research and Development Partnership","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ The Global Antibiotic Research and Development Partnership"},{"orgOrder":0,"company":"Innoviva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"||DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innoviva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva \/ Undisclosed"},{"orgOrder":0,"company":"Innoviva Specialty Therapeutics","sponsor":"Global Antibiotic Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Zoliflodacin","moa":"DNA gyrase | Topoisomerase IV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Innoviva Specialty Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Innoviva Specialty Therapeutics \/ Global Antibiotic Research & Development","highestDevelopmentStatusID":"10","companyTruncated":"Innoviva Specialty Therapeutics \/ Global Antibiotic Research & Development"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Department of Health and Human Services","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Department of Health and Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Department of Health and Human Services"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Collaboration","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Funding","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Summit Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Summit Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Summit Biosciences","sponsor":"Polar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Private Placement","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Summit Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Summit Biosciences \/ Polar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Summit Biosciences \/ Polar Capital"},{"orgOrder":0,"company":"Quest Products","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Financing","leadProduct":"Ridinilazole","moa":"DNA minor groove","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quest Products","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Quest Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Quest Products \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pradefovir Mesylate","moa":"DNA polymerase\/reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"University of Wisconsin, Madison","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Wisconsin, Madison","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Wisconsin, Madison \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Wisconsin, Madison \/ Merck & Co"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CPI-006","moa":"Ecto-5'-nucleotidase (CD73)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Corvus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CPI-006","moa":"Ecto-5'-nucleotidase (CD73)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Corvus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corvus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Corvus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tafenoquine","moa":"Electron transport complex III (Complex III)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Apices Soluciones","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Apices Soluciones","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Apices Soluciones"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Plitidepsin","moa":"Elongation factor 1-alpha 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"Baxis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fusidic Acid","moa":"Elongation factor G","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Baxis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Baxis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Trimodulin","moa":"Endotoxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Trimodulin","moa":"Endotoxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biotest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ SIGA Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ SIGA Technologies"},{"orgOrder":0,"company":"Marina Klein","sponsor":"McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Marina Klein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marina Klein \/ McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network","highestDevelopmentStatusID":"10","companyTruncated":"Marina Klein \/ McGill University Health Centre Research Institute | University Health Network, Toronto | Unity Health Toronto | University of British Columbia | CIHR Canadian HIV Trials Network"},{"orgOrder":0,"company":"Bharat Serums & Vaccines ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Urinastatin","moa":"enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Serums & Vaccines ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Serums & Vaccines ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Serums & Vaccines ltd \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Camostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dipyridamole","moa":"Equilibrative nucleoside transporter 1 | 3',5'-cyclic phosphodiesterase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers, The State University of New Jersey \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Rutgers, The State University of New Jersey \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ University of Minnesota","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ University of Minnesota"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Amphotericin B","moa":"||Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"CSPC Ouyi Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amphotericin B Cholesteryl Sulfate Complex","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSPC Ouyi Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CSPC Ouyi Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Georgia State University","sponsor":"Gilead Sciences | Financiadora de Estudos e Projetos | Sociedade Gaucha de Infectologia | Immuno-mycologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Amphotericin B","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Georgia State University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Georgia State University \/ Gilead Sciences | Financiadora de Estudos e Projetos | Sociedade Gaucha de Infectologia | Immuno-mycologics","highestDevelopmentStatusID":"10","companyTruncated":"Georgia State University \/ Gilead Sciences | Financiadora de Estudos e Projetos | Sociedade Gaucha de Infectologia | Immuno-mycologics"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MAT2203","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Matinas BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matinas BioPharma \/ University of Minnesota","highestDevelopmentStatusID":"10","companyTruncated":"Matinas BioPharma \/ University of Minnesota"},{"orgOrder":0,"company":"Avva Rus JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Natamycin","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Avva Rus JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Avva Rus JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avva Rus JSC \/ Undisclosed"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ GHIT Fund"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia","highestDevelopmentStatusID":"10","companyTruncated":"London School of Hygiene & Tropical Medicine \/ Institut Pasteur | Institut Pasteur de Madagascar | Armauer Hansen Research Institute (AHRI), Ethiopia"},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Chloroquine Phosphate","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Washington University School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"PATH","sponsor":"Federal Minstry of Health of Ethiopia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ Federal Minstry of Health of Ethiopia","highestDevelopmentStatusID":"10","companyTruncated":"PATH \/ Federal Minstry of Health of Ethiopia"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"Sanofi","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ AstraZeneca"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilematovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Ark Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ziresovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Ark Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Ark Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ziresovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Ark Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Ark Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ziresovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Ark Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Ark Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Ark Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ziresovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ark Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ark Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ark Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bioxytran","sponsor":"ALKE RESEARCH | Research Consultancy","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ ALKE RESEARCH | Research Consultancy","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ ALKE RESEARCH | Research Consultancy"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Alke Research Private Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Alke Research Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Alke Research Private Limited"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Triton Funds","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Private Placement","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Triton Funds","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Triton Funds"},{"orgOrder":0,"company":"Bioxytran","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Galactomannan","moa":"Galectin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bioxytran","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Bioxytran \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bioxytran \/ Undisclosed"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Moxidectin","moa":"Gamma-aminobutyric acid receptor (GAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicines Development for Global Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medicines Development for Global Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardresearch","sponsor":"Cytel | McMaster University | Fastgrants | Eiger BioPharmaceuticals | RainWater Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cardresearch","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cardresearch \/ Cytel | McMaster University | Fastgrants | Eiger BioPharmaceuticals | RainWater Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Cardresearch \/ Cytel | McMaster University | Fastgrants | Eiger BioPharmaceuticals | RainWater Foundation"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"LUXEMBOURG","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Ciclesonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Covis Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Covis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Universitario Infanta Leonor","sponsor":"Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor | Kern Pharma S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Universitario Infanta Leonor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitario Infanta Leonor \/ Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor | Kern Pharma S.L.","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Universitario Infanta Leonor \/ Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor | Kern Pharma S.L."},{"orgOrder":0,"company":"Karolinska Institutet","sponsor":"Scandinavian Critical Care Trials Group | Copenhagen Trial Unit, Center for Clinical Intervention Research | Centre for Research in Intensive Care | Aarhus University Hospital | Aalborg University | Rigshospitalet | Linkoeping University | Stockholm South","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Karolinska Institutet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska Institutet \/ Scandinavian Critical Care Trials Group | Copenhagen Trial Unit, Center for Clinical Intervention Research | Centre for Research in Intensive Care | Aarhus University Hospital | Aalborg University | Rigshospitalet | Linkoeping University | Stockholm South","highestDevelopmentStatusID":"10","companyTruncated":"Karolinska Institutet \/ Scandinavian Critical Care Trials Group | Copenhagen Trial Unit, Center for Clinical Intervention Research | Centre for Research in Intensive Care | Aarhus University Hospital | Aalborg University | Rigshospitalet | Linkoeping University | Stockholm South"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Sirio-Libanes","sponsor":"Hospital Israelita Albert Einstein | Hospital do Coracao | Brazilian Research In Intensive Care Network | Ache Laboratorios Farmaceuticos SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Sirio-Libanes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Sirio-Libanes \/ Hospital Israelita Albert Einstein | Hospital do Coracao | Brazilian Research In Intensive Care Network | Ache Laboratorios Farmaceuticos SA","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Sirio-Libanes \/ Hospital Israelita Albert Einstein | Hospital do Coracao | Brazilian Research In Intensive Care Network | Ache Laboratorios Farmaceuticos SA"},{"orgOrder":0,"company":"Scandinavian Critical Care Trials Group","sponsor":"Copenhagen Trial Unit, Center for Clinical Intervention Research | Centre for Research in Intensive Care | Aarhus University Hospital | Aalborg University | Rigshospitalet | The George Institute for Global Health, Australia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scandinavian Critical Care Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scandinavian Critical Care Trials Group \/ Copenhagen Trial Unit, Center for Clinical Intervention Research | Centre for Research in Intensive Care | Aarhus University Hospital | Aalborg University | Rigshospitalet | The George Institute for Global Health, Australia","highestDevelopmentStatusID":"10","companyTruncated":"Scandinavian Critical Care Trials Group \/ Copenhagen Trial Unit, Center for Clinical Intervention Research | Centre for Research in Intensive Care | Aarhus University Hospital | Aalborg University | Rigshospitalet | The George Institute for Global Health, Australia"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Scandinavian Critical Care Trials Group","sponsor":"Rigshospitalet | Copenhagen Trial Unit, Center for Clinical Intervention Research | University of Copenhagen | Aarhus University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scandinavian Critical Care Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scandinavian Critical Care Trials Group \/ Rigshospitalet | Copenhagen Trial Unit, Center for Clinical Intervention Research | University of Copenhagen | Aarhus University Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Scandinavian Critical Care Trials Group \/ Rigshospitalet | Copenhagen Trial Unit, Center for Clinical Intervention Research | University of Copenhagen | Aarhus University Hospital"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"LianBio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ LianBio","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ LianBio"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Private Placement","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant, Sustained Release","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lyra Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2025","type":"Public Offering","leadProduct":"Mometasone Furoate","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lyra Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Lyra Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Lyra Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Optinose","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"OPN-375","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Optinose","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optinose \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Optinose \/ Undisclosed"},{"orgOrder":0,"company":"Valentina Puentmann","sponsor":"Bayer AG | Alcedis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valentina Puentmann","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valentina Puentmann \/ Bayer AG | Alcedis","highestDevelopmentStatusID":"10","companyTruncated":"Valentina Puentmann \/ Bayer AG | Alcedis"},{"orgOrder":0,"company":"Clinical Research Centre, Malaysia","sponsor":"Hovid BHD","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MALAYSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clinical Research Centre, Malaysia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Research Centre, Malaysia \/ Hovid BHD","highestDevelopmentStatusID":"10","companyTruncated":"Clinical Research Centre, Malaysia \/ Hovid BHD"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"MRC Unit, The Gambia | Ministerio de Saude Publica, Guinee-Bissau | Bandim Health Project | Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"London School of Hygiene & Tropical Medicine \/ MRC Unit, The Gambia | Ministerio de Saude Publica, Guinee-Bissau | Bandim Health Project | Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau","highestDevelopmentStatusID":"10","companyTruncated":"London School of Hygiene & Tropical Medicine \/ MRC Unit, The Gambia | Ministerio de Saude Publica, Guinee-Bissau | Bandim Health Project | Instituto Nacional de Estudos e Pesquisas, Guinee-Bissau"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"GKM Gesellschaft f\u00fcr Therapieforschung","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"InfectoPharm Drugs and Consilium \/ GKM Gesellschaft f\u00fcr Therapieforschung","highestDevelopmentStatusID":"10","companyTruncated":"InfectoPharm Drugs and Consilium \/ GKM Gesellschaft f\u00fcr Therapieforschung"},{"orgOrder":0,"company":"Insud Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Insud Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Insud Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insud Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Afyonkarahisar Health Sciences University","sponsor":"NeuTec Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Afyonkarahisar Health Sciences University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Afyonkarahisar Health Sciences University \/ NeuTec Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Afyonkarahisar Health Sciences University \/ NeuTec Pharma"},{"orgOrder":0,"company":"Supriya Lifescience","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Amino Acid","year":"2021","type":"Collaboration","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Supriya Lifescience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Supriya Lifescience \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Supriya Lifescience \/ Revive Therapeutics"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ University of California","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ University of California"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Canaccord Genuity"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Delta Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Delta Health","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Delta Health"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"EMD Financial","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ EMD Financial","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ EMD Financial"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Private Placement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Attwill Medical Solutions","sponsor":"Revive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Agreement","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Attwill Medical Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Attwill Medical Solutions \/ Revive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Attwill Medical Solutions \/ Revive Therapeutics"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Revive Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Revive Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Universidade Federal do Ceara","sponsor":"Paulista School of Medicine-EPM, UNIFESP | Health Surveillance Secretariat - SVS | Central Laboratory of Public Health of Ceara - LACEN-CE | Leonardo da Vinci Hospital | S\u00e3o Jos\u00e9 Hospital for Infectious Diseases - HSJ | Cear\u00e1 Health Secretariat - SESA | M","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Universidade Federal do Ceara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidade Federal do Ceara \/ Paulista School of Medicine-EPM, UNIFESP | Health Surveillance Secretariat - SVS | Central Laboratory of Public Health of Ceara - LACEN-CE | Leonardo da Vinci Hospital | S\u00e3o Jos\u00e9 Hospital for Infectious Diseases - HSJ | Cear\u00e1 Health Secretariat - SESA | M","highestDevelopmentStatusID":"10","companyTruncated":"Universidade Federal do Ceara \/ Paulista School of Medicine-EPM, UNIFESP | Health Surveillance Secretariat - SVS | Central Laboratory of Public Health of Ceara - LACEN-CE | Leonardo da Vinci Hospital | S\u00e3o Jos\u00e9 Hospital for Infectious Diseases - HSJ | Cear\u00e1 Health Secretariat - SESA | M"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isoflurane","moa":"Glycine receptor (alpha-1\/beta) | Potassium channel subfamily K member 18 | Potassium channel subfamily K member 9 | Potassium channel subfamily K member 2 | GABA-A receptor; anion channel | Potassium channel subfamily K member 3 | Potassium channel subfamily K member 10","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Larkin Community Hospital","sponsor":"Ferrer Internacional | Xlear, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation||Xylose isomerase; Xylose isomerase; Xylose isomerase; Xylose isomerase; Hyaluronate lyase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Larkin Community Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Larkin Community Hospital \/ Ferrer Internacional | Xlear, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Larkin Community Hospital \/ Ferrer Internacional | Xlear, Inc"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Albuvirtide","moa":"||GP41","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Albuvirtide","moa":"GP41","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Albuvirtide","moa":"GP41","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Albuvirtide","moa":"GP41","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Basilea Pharmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Basilea Pharmaceutica"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Swiss Tropical and Public Health Institute","sponsor":"Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swiss Tropical and Public Health Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Tropical and Public Health Institute \/ Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Swiss Tropical and Public Health Institute \/ Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation"},{"orgOrder":0,"company":"Swiss Tropical and Public Health Institute","sponsor":"Bayer AG | Silicon Valley Community Foundation | University of the Philippines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swiss Tropical and Public Health Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Tropical and Public Health Institute \/ Bayer AG | Silicon Valley Community Foundation | University of the Philippines","highestDevelopmentStatusID":"10","companyTruncated":"Swiss Tropical and Public Health Institute \/ Bayer AG | Silicon Valley Community Foundation | University of the Philippines"},{"orgOrder":0,"company":"Chime Biologics","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chime Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chime Biologics \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Chime Biologics \/ Humanigen"},{"orgOrder":0,"company":"Ajinomoto Bio-Pharma","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ajinomoto Bio-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Bio-Pharma \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Bio-Pharma \/ Humanigen"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Humanigen","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Clinigen Group"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"KPM Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Licensing Agreement","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ KPM Tech","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ KPM Tech"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Humanigen"},{"orgOrder":0,"company":"Lonza Biologics Inc","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lonza Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lonza Biologics Inc \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Lonza Biologics Inc \/ Humanigen"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Public Offering","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ J.P. Morgan"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Thermo Fisher Scientific \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Thermo Fisher Scientific \/ Humanigen"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Humanigen"},{"orgOrder":0,"company":"Humanigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"PCI Pharma Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ PCI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ PCI Pharma Services"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Humanigen","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Lenzilumab","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Humanigen \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Humanigen \/ National Institutes of Health"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Humanigen"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Kiniksa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Kiniksa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Kiniksa Pharmaceuticals"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Guanylate cyclase (GC)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ondine Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Guanylate cyclase (GC)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ondine Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Healthcare's Memorial Health University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Guanylate cyclase (GC)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Guanylate cyclase (GC)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ondine Biomedical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Bacthera","sponsor":"Seres Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bacthera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bacthera \/ Seres Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Bacthera \/ Seres Therapeutics"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0.53000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.53000000000000003,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Public Offering","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Seres Therapeutics","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Firmicute Species Bacterial Spore","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seres Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seres Therapeutics \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"10","companyTruncated":"Seres Therapeutics \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Shanghai Institute of Biological Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Institute of Biological Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Institute of Biological Products \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tobevibart","moa":"HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Elebsiran","moa":"||HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tobevibart","moa":"HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Tobevibart","moa":"HBV","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AiCuris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pritelivir","moa":"Helicase\/primase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AiCuris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AiCuris \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AiCuris \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhimeng Biopharma \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Zhimeng Biopharma \/ Tigermed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Zhimeng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Zhimeng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Zhimeng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Zhimeng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efprezimod Alfa","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.42999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.42999999999999999,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Hm Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Hm Capital","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Hm Capital"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"MK-7110","moa":"High mobility group protein B1 | Heat shock 70 kDa protein 1A\/1B | Sialic acid-binding Ig-like lectin 10 | Heat shock protein HSP90","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0.35999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.35999999999999999,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ US Government","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ US Government"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"National University of Singapore","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ National University of Singapore","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ National University of Singapore"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody-peptide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Ergoferon","moa":"Histamine H1 receptor \/ Immune system","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Boston University School of Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boston University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Boston University School of Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boston University School of Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Cold Spring Harbor Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Cold Spring Harbor Laboratory","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Cold Spring Harbor Laboratory"},{"orgOrder":0,"company":"Judit Pich Mart\u00ednez","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bictegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Judit Pich Mart\u00ednez","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Judit Pich Mart\u00ednez \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Judit Pich Mart\u00ednez \/ Gilead Sciences"},{"orgOrder":0,"company":"Precigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"HPV6\/HPV11","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ Undisclosed"},{"orgOrder":0,"company":"Precigen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Zopapogene Imadenovec","moa":"HPV6\/HPV11","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precigen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Precigen \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acyclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Nika Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Agreement","leadProduct":"ITV-1","moa":"Human immunodeficiency virus Glycoprotein 41 (HIV gp41)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nika Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nika Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nika Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Witwatersrand, South Africa","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Witwatersrand, South Africa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University of Witwatersrand, South Africa \/ ViiV Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"University of Witwatersrand, South Africa \/ ViiV Healthcare"},{"orgOrder":0,"company":"MRC\/UVRI and LSHTM Uganda Research Unit","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UGANDA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MRC\/UVRI and LSHTM Uganda Research Unit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRC\/UVRI and LSHTM Uganda Research Unit \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"MRC\/UVRI and LSHTM Uganda Research Unit \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"University College, London","sponsor":"European & Developing Countries Clinical Trials Partnership | Janssen-Cilag | ViiV Healthcare | Department of Clinical Pharmacy, University Medical Centre St Radboud | London School of Hygiene & Tropical Medicine | MRC\/UVRI and LSHTM Uganda Research Unit ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University College, London \/ European & Developing Countries Clinical Trials Partnership | Janssen-Cilag | ViiV Healthcare | Department of Clinical Pharmacy, University Medical Centre St Radboud | London School of Hygiene & Tropical Medicine | MRC\/UVRI and LSHTM Uganda Research Unit ","highestDevelopmentStatusID":"10","companyTruncated":"University College, London \/ European & Developing Countries Clinical Trials Partnership | Janssen-Cilag | ViiV Healthcare | Department of Clinical Pharmacy, University Medical Centre St Radboud | London School of Hygiene & Tropical Medicine | MRC\/UVRI and LSHTM Uganda Research Unit "},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"ViiV Healthcare | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ ViiV Healthcare | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johns Hopkins University \/ ViiV Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Johns Hopkins University \/ ViiV Healthcare"},{"orgOrder":0,"company":"Funda\u00e7\u00e3o Bahiana de Infectologia","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Funda\u00e7\u00e3o Bahiana de Infectologia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Funda\u00e7\u00e3o Bahiana de Infectologia \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Funda\u00e7\u00e3o Bahiana de Infectologia \/ GSK"},{"orgOrder":0,"company":"NEAT ID Foundation","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NEAT ID Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NEAT ID Foundation \/ ViiV Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"NEAT ID Foundation \/ ViiV Healthcare"},{"orgOrder":0,"company":"Coripharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ICELAND","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Coripharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Coripharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Coripharma \/ Midas Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Darunavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Darunavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Drugs For Neglected Diseases Initiative","sponsor":"Inserm-ANRS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Drugs For Neglected Diseases Initiative","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drugs For Neglected Diseases Initiative \/ Inserm-ANRS","highestDevelopmentStatusID":"10","companyTruncated":"Drugs For Neglected Diseases Initiative \/ Inserm-ANRS"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ring","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"International Partnership for Microbicides \/ Undisclosed"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"Merck & Co | European & Developing Countries Clinical Trials Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANRS, Emerging Infectious Diseases \/ Merck & Co | European & Developing Countries Clinical Trials Partnership","highestDevelopmentStatusID":"10","companyTruncated":"ANRS, Emerging Infectious Diseases \/ Merck & Co | European & Developing Countries Clinical Trials Partnership"},{"orgOrder":0,"company":"Prism Health North Texas","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Prism Health North Texas","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prism Health North Texas \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Prism Health North Texas \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Professor Francois Venter","sponsor":"Africa Health Research Institute | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doravirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Professor Francois Venter","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Professor Francois Venter \/ Africa Health Research Institute | Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Professor Francois Venter \/ Africa Health Research Institute | Merck & Co"},{"orgOrder":0,"company":"Plan Nacional sobre el Sida","sponsor":"Effice Servicios Para la Investigacion","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emtricitabine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Plan Nacional sobre el Sida","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Plan Nacional sobre el Sida \/ Effice Servicios Para la Investigacion","highestDevelopmentStatusID":"10","companyTruncated":"Plan Nacional sobre el Sida \/ Effice Servicios Para la Investigacion"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"Chiang Mai University | Ministry of Health, Thailand | Assistance Publique \u2013 H\u00f4pitaux de Paris | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANRS, Emerging Infectious Diseases \/ Chiang Mai University | Ministry of Health, Thailand | Assistance Publique \u2013 H\u00f4pitaux de Paris | Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"ANRS, Emerging Infectious Diseases \/ Chiang Mai University | Ministry of Health, Thailand | Assistance Publique \u2013 H\u00f4pitaux de Paris | Gilead Sciences"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"University of Cape Town | Desmond Tutu HIV Foundation | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ University of Cape Town | Desmond Tutu HIV Foundation | Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"University of California, Los Angeles \/ University of Cape Town | Desmond Tutu HIV Foundation | Gilead Sciences"},{"orgOrder":0,"company":"MRC\/UVRI and LSHTM Uganda Research Unit","sponsor":"King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique \u2013 H\u00f4pitaux de Pa","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UGANDA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tenofovir Disoproxil Fumarate","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MRC\/UVRI and LSHTM Uganda Research Unit","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MRC\/UVRI and LSHTM Uganda Research Unit \/ King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique \u2013 H\u00f4pitaux de Pa","highestDevelopmentStatusID":"10","companyTruncated":"MRC\/UVRI and LSHTM Uganda Research Unit \/ King's College London | London School of Hygiene & Tropical Medicine | Africa Health Research Institute | Wits Health Consortium | University College, London | Ministry of Health, Uganda | Desmond Tutu HIV Foundation | Assistance Publique \u2013 H\u00f4pitaux de Pa"},{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Gilead Sciences"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Islatravir","moa":"Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Islatravir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase | Reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VGX-3100","moa":"Human papillomavirus protein E6 (HPV E6)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Petrovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Bovhyaluronidase Azoximer","moa":"Hyaluronidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Petrovax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Kawin Technology Share-Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Peginterferon Alfacon-2","moa":"IFN-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Kawin Technology Share-Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Kawin Technology Share-Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Kawin Technology Share-Holding \/ Undisclosed"},{"orgOrder":0,"company":"VirTrial","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Partnership","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VirTrial","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"VirTrial \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"VirTrial \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"List Biological Laboratories","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"List Biological Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"List Biological Laboratories \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"List Biological Laboratories \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"BetterLife Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ BetterLife Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ BetterLife Pharma"},{"orgOrder":0,"company":"Altum Pharmaceuticals","sponsor":"Pontificia Universidad Catolica de Chile","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AP-003","moa":"IFN-alpha\/IFN-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Altum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray, Metered","sponsorNew":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile","highestDevelopmentStatusID":"10","companyTruncated":"Altum Pharmaceuticals \/ Pontificia Universidad Catolica de Chile"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Interferon Alpha","moa":"IFNAR-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Human Interferon Alpha","moa":"IFNAR-1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"C19-IG","moa":"IgG","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"LY3650150","moa":"IL-13 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Provectus Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Rose Bengal Sodium","moa":"||IL-17 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Provectus Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Provectus Biopharmaceuticals"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"CM310","moa":"IL-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"GR1802","moa":"IL-4R?","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Council of Scientific and Industrial Research, India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Autoclaved Mycobacterium W","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cadila Pharmaceuticals \/ Council of Scientific and Industrial Research, India","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Council of Scientific and Industrial Research, India"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Council of Scientific and Industrial Research, India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Autoclaved Mycobacterium W","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cadila Pharmaceuticals \/ Council of Scientific and Industrial Research, India","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Council of Scientific and Industrial Research, India"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Council of Scientific and Industrial Research, India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Autoclaved Mycobacterium W","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Cadila Pharmaceuticals \/ Council of Scientific and Industrial Research, India","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Council of Scientific and Industrial Research, India"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bacillus Calmette-Gu\u00e9rin Vaccine","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Nielsen BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Candida Albicans Skin Test Antigen","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nielsen BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nielsen BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nielsen BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Nielsen BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Candida Albicans Skin Test Antigen","moa":"Immune||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nielsen BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nielsen BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nielsen BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Canadian Blood Services | H\u00e9ma-Qu\u00e9bec | University of Toronto | Universit\u00e9 de Montr\u00e9al | Weill Medical College of Cornell University | New York Blood Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Convalescent Plasma","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hamilton Health Sciences \/ Canadian Blood Services | H\u00e9ma-Qu\u00e9bec | University of Toronto | Universit\u00e9 de Montr\u00e9al | Weill Medical College of Cornell University | New York Blood Center","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ Canadian Blood Services | H\u00e9ma-Qu\u00e9bec | University of Toronto | Universit\u00e9 de Montr\u00e9al | Weill Medical College of Cornell University | New York Blood Center"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Prothya Biosolutions | ZonMw | Leiden University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Convalescent Plasma","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions | ZonMw | Leiden University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions | ZonMw | Leiden University Medical Center"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Prothya Biosolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Convalescent Plasma","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Prothya Biosolutions"},{"orgOrder":0,"company":"Jiangsu Famous Medical Technology","sponsor":"Ruijin Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Tanreqing","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Famous Medical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Famous Medical Technology \/ Ruijin Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Famous Medical Technology \/ Ruijin Hospital"},{"orgOrder":0,"company":"Atox Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Reltecimod","moa":"immunomodulators","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atox Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atox Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atox Bio \/ Undisclosed"},{"orgOrder":0,"company":"Wockhardt","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wockhardt \/ US Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ US Government"},{"orgOrder":0,"company":"Wockhardt","sponsor":"UK Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wockhardt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Wockhardt \/ UK Government","highestDevelopmentStatusID":"10","companyTruncated":"Wockhardt \/ UK Government"},{"orgOrder":0,"company":"Halix BV","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Halix BV \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/ AstraZeneca"},{"orgOrder":0,"company":"Halix BV","sponsor":"University\u2019S Jenner Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Halix BV \/ University\u2019S Jenner Institute","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/ University\u2019S Jenner Institute"},{"orgOrder":0,"company":"Curia","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Curia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curia \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Curia \/ AstraZeneca"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ AstraZeneca"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ AstraZeneca"},{"orgOrder":0,"company":"Anvisa","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anvisa","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anvisa \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anvisa \/ Undisclosed"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enisamium Iodide","moa":"Influenza virus RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FARMAK, a.s \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FARMAK, a.s \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"||Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"||Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"P1101","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"PharmaEssentia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Xiamen Amoytop Biotech Co., Ltd","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Xiamen Amoytop Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Amoytop Biotech Co., Ltd \/ Peking University First Hospital"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"University of Southampton","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ University of Southampton","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ University of Southampton"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ National Institutes of Health"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Synairgen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"SNG001","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synairgen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Synairgen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Synairgen \/ Undisclosed"},{"orgOrder":0,"company":"Polysan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Cycloferon","moa":"Interferon inducer","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Polysan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Polysan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polysan \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Peginterferon Lambda-1a","moa":"Interferon lambda receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Genova Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Novaferon","moa":"Interferon-alpha 2 (IFNA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genova Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genova Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genova Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Genova Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Novaferon","moa":"Interferon-alpha 2 (IFNA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genova Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genova Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genova Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Genova Inc.","sponsor":"Tokyo Shinagawa Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Novaferon","moa":"Interferon-alpha 2 (IFNA2)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genova Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genova Inc. \/ Tokyo Shinagawa Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Genova Inc. \/ Tokyo Shinagawa Hospital"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Interferon-alpha\/beta-receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Basel","sponsor":"Novartis Pharmaceuticals Corporation | Swiss National Science Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospital, Basel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"University Hospital, Basel \/ Novartis Pharmaceuticals Corporation | Swiss National Science Foundation","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Basel \/ Novartis Pharmaceuticals Corporation | Swiss National Science Foundation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Belgium Health Care Knowledge Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital Ghent \/ Belgium Health Care Knowledge Centre"},{"orgOrder":0,"company":"University Hospital, Tours","sponsor":"INSERM CIC-P 1415, University Hospital Center of Tours | Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospital, Tours","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Hospital, Tours \/ INSERM CIC-P 1415, University Hospital Center of Tours | Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Tours \/ INSERM CIC-P 1415, University Hospital Center of Tours | Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Hellenic Institute for the Study of Sepsis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Hellenic Institute for the Study of Sepsis"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Itepekimab","moa":"Interleukin-33","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Itepekimab","moa":"Interleukin-33","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"||Interleukin-5 receptor subunit alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Benralizumab","moa":"||Interleukin-5 receptor subunit alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"George Mason University | Medsi Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ George Mason University | Medsi Group","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ George Mason University | Medsi Group"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Cromos Pharma | Covance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Cromos Pharma | Covance","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Cromos Pharma | Covance"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Olokizumab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eusa Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biocad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Levilimab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Sarilumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Abderrahmane Mami Hospital","sponsor":"Gangnam Severance Hospital | Datametrix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TUNISIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Abderrahmane Mami Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix","highestDevelopmentStatusID":"10","companyTruncated":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Brigham and Women's Hospital \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Brigham and Women's Hospital \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Massachusetts General Hospital \/ Genentech"},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hackensack Meridian CDI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hackensack Meridian CDI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian CDI \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reparixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reparixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Reparixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Reparixin","moa":"Interleukin-8 receptor A | Interleukin-8 receptor B","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Lublin","sponsor":"Pharmabest Sp. z o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Bovine Lactoferrin","moa":"Iron","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medical University of Lublin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medical University of Lublin \/ Pharmabest Sp. z o.o.","highestDevelopmentStatusID":"10","companyTruncated":"Medical University of Lublin \/ Pharmabest Sp. z o.o."},{"orgOrder":0,"company":"Reig Jofre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Mupirocin","moa":"Isoleucyl-tRNA synthetase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Reig Jofre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Reig Jofre \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Reig Jofre \/ Undisclosed"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tofacitinib Citrate","moa":"Janus Kinase (JAK)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Israelita Albert Einstein \/ Pfizer Inc"},{"orgOrder":0,"company":"Jeffrey Jenks","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isavuconazonium Sulfate","moa":"Lanosterol 14-alpha demethylase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jeffrey Jenks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jeffrey Jenks \/ Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Jeffrey Jenks \/ Astellas Pharma"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Quantum Leap Healthcare","sponsor":"Omeros","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Quantum Leap Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Quantum Leap Healthcare \/ Omeros","highestDevelopmentStatusID":"10","companyTruncated":"Quantum Leap Healthcare \/ Omeros"},{"orgOrder":0,"company":"Omeros","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Narsoplimab","moa":"Mannan-binding lectin serine protease 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Omeros \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Omeros \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAP kinase p38 alpha | MAP kinase p38 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAP kinase p38 alpha | MAP kinase p38 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Losmapimod","moa":"MAP kinase p38 alpha | MAP kinase p38 beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"SGS Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ SGS Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ SGS Life Sciences"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Private Placement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biophytis","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Biophytis","sponsor":"Intsel Chimos","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Intsel Chimos","highestDevelopmentStatusID":"10","companyTruncated":"Biophytis \/ Intsel Chimos"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Paste","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Doxycycline","moa":"Matrix metalloproteinase 13 | Bacterial 70S ribosome | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Matrix metalloproteinase 8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Advanz Pharma"},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Citizens JMP"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"JMP Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ JMP Securities","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ JMP Securities"},{"orgOrder":0,"company":"PolyPid","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Kreos Capital"},{"orgOrder":0,"company":"PolyPid","sponsor":"Citizens JMP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Citizens JMP","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Citizens JMP"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Private Placement","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Powder, Extended Release","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Aurum Ventures"},{"orgOrder":0,"company":"PolyPid","sponsor":"Aurum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ Aurum Ventures","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Aurum Ventures"},{"orgOrder":0,"company":"PolyPid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Doxycycline Hyclate","moa":"Matrix metalloproteinase 8 | Matrix metalloproteinase 13 | Matrix metalloproteinase 7 | Matrix metalloproteinase-1 | Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PolyPid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolyPid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PolyPid \/ Undisclosed"},{"orgOrder":0,"company":"Noblewell","sponsor":"Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amantadine Hydrochloride","moa":"Matrix protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Noblewell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noblewell \/ Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre","highestDevelopmentStatusID":"10","companyTruncated":"Noblewell \/ Medical Research Agency Poland | Leszek Giec Upper-Silesian Medical Centre"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"United Health Group | Northwestern University | Hennepin County Medical Center, Minneapolis | University of Colorado, Denver | Olive View-UCLA Education & Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ United Health Group | Northwestern University | Hennepin County Medical Center, Minneapolis | University of Colorado, Denver | Olive View-UCLA Education & Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"University of Minnesota \/ United Health Group | Northwestern University | Hennepin County Medical Center, Minneapolis | University of Colorado, Denver | Olive View-UCLA Education & Research Institute"},{"orgOrder":0,"company":"Purpose Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Purpose Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purpose Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Purpose Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tozorakimab","moa":"monoclonal antibodies: interleukins","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STI-1558","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang ACEA Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"STI-1558","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang ACEA Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STI-1558","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang ACEA Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang ACEA Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"STI-1558","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang ACEA Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang ACEA Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"||mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Bepirovirsen","moa":"||mRNA","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine","moa":"Neisseria meningitidis polysaccharide\/Tetanus toxoid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine","moa":"Neisseria meningitidis polysaccharide\/Tetanus toxoid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine","moa":"Neisseria meningitidis polysaccharide\/Tetanus toxoid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine","moa":"Neisseria meningitidis polysaccharide\/Tetanus toxoid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine","moa":"Neisseria meningitidis polysaccharide\/Tetanus toxoid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Tetanus Toxoid Conjugate Vaccine","moa":"Neisseria meningitidis polysaccharide\/Tetanus toxoid","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.78000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.78000000000000003,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ GSK"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.78000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.78000000000000003,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ GSK"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ GSK"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23999999999999999,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.25,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zanamivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Northwell Health \/ Vanda Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Northwell Health \/ Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tradipitant","moa":"Neurokinin 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zurex Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Isopropyl Alcohol","moa":"Nitric oxide synthase 3; Oxysterols receptor LXR-beta; Heme oxygenase 1; GTP cyclohydrolase 1; Phospholipase A2, membrane associated; Tumor necrosis factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zurex Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Zurex Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zurex Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PROFESSIONAL DISPOSABLES INTERNATIONAL","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Isopropyl Alcohol","moa":"Nitric oxide synthase 3; Oxysterols receptor LXR-beta; Heme oxygenase 1; GTP cyclohydrolase 1; Phospholipase A2, membrane associated; Tumor necrosis factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PROFESSIONAL DISPOSABLES INTERNATIONAL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PROFESSIONAL DISPOSABLES INTERNATIONAL \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PROFESSIONAL DISPOSABLES INTERNATIONAL \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pterostilbene","moa":"||NLRP3","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Finch Research and Development LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Research and Development LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Finch Research and Development LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Research and Development LLC \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Baupost Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Series D Financing","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Baupost Group","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Baupost Group"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Finch Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"CP101","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Finch Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Finch Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Finch Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MK-8591A","moa":"NRTT","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"20-valent Pneumococcal Conjugate Vaccine","moa":"||Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pneumococcal 15-valent Conjugate Vaccine","moa":"Opsonophagocytosis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Quark Venture LP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series D Financing","leadProduct":"Zegocractin","moa":"ORAI1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Quark Venture LP","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedica \/ Quark Venture LP"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Zegocractin","moa":"ORAI1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Zegocractin","moa":"ORAI1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CalciMedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CalciMedica \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ GSK"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.81999999999999995,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ GSK"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Licensing Agreement","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.81999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.81999999999999995,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ GSK"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spero Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Spero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Spero Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spero Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Benova (Tianjin) Innovative Medicine Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Pivmecillinam","moa":"penicillins","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Benova (Tianjin) Innovative Medicine Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Benova (Tianjin) Innovative Medicine Research \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Benova (Tianjin) Innovative Medicine Research \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Centre Hospitalier de Perigueux | Advanz Pharma | Nantes University Hospital | Centre National de R\u00e9f\u00e9rence des staphylocoques","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dalbavancin","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Centre Hospitalier de Perigueux | Advanz Pharma | Nantes University Hospital | Centre National de R\u00e9f\u00e9rence des staphylocoques","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Centre Hospitalier de Perigueux | Advanz Pharma | Nantes University Hospital | Centre National de R\u00e9f\u00e9rence des staphylocoques"},{"orgOrder":0,"company":"Savara","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Savara","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Savara \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Savara \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ BARDA"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"ContraFect Corporation \/ SVB Leerink","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ SVB Leerink"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Mizuho Securities Usa Llc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Public Offering","leadProduct":"Exebacase","moa":"Peptidoglycan | Biofilm","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ContraFect Corporation \/ Mizuho Securities Usa Llc","highestDevelopmentStatusID":"10","companyTruncated":"ContraFect Corporation \/ Mizuho Securities Usa Llc"},{"orgOrder":0,"company":"Yaakov Nahmias","sponsor":"Barzilai Medical Center | Rambam Health Care Campus | Nazareth Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fenofibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yaakov Nahmias","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Yaakov Nahmias \/ Barzilai Medical Center | Rambam Health Care Campus | Nazareth Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Yaakov Nahmias \/ Barzilai Medical Center | Rambam Health Care Campus | Nazareth Hospital"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Verona Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Verona Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Verona Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Verona Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Monash University","highestDevelopmentStatusID":"10","companyTruncated":"Bayside Health \/ Monash University"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Jiangxi Kerui Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Suraxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangxi Kerui Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jiangxi Kerui Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangxi Kerui Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pimodivir","moa":"Polymerase basic protein 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Novan","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Gel","sponsorNew":"Novan \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Novan","sponsor":"EPI Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ EPI Health","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ EPI Health"},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Novan","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Gel","sponsorNew":"Novan \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Novan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Undisclosed"},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Novan","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Divestment","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Novan","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Gel","sponsorNew":"Novan \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"iNtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fexuprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ iNtherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ iNtherapeutics"},{"orgOrder":0,"company":"Luoxin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Luoxin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Luoxin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Luoxin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"HK inno.N","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tegoprazan","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HK inno.N","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK inno.N \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HK inno.N \/ Undisclosed"},{"orgOrder":0,"company":"Aga Khan University","sponsor":"Searle Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aga Khan University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aga Khan University \/ Searle Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Aga Khan University \/ Searle Pharmaceuticals"},{"orgOrder":0,"company":"SLA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain; Acyl-CoA (8-3)-desaturase; Long-chain-fatty-acid--CoA ligase 4; Transient receptor potential cation channel subfamily V member 1; Peroxisome proliferator-activated receptor alpha; Polyunsaturated fatty acid 5-lipoxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SLA Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SLA Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SLA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leonard-Meron Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mino-Lok","moa":"Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Leonard-Meron Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Leonard-Meron Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leonard-Meron Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Soroka University Medical Center","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Soroka University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Soroka University Medical Center \/ Eiger BioPharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Soroka University Medical Center \/ Eiger BioPharmaceuticals"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Protein farnesyltransferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Protein farnesyltransferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"||Protein farnesyltransferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HebaBiz Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Clevudine","moa":"Protein P","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HebaBiz Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"HebaBiz Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"HebaBiz Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus","sponsor":"Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Azidus \/ Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian","highestDevelopmentStatusID":"10","companyTruncated":"Azidus \/ Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Romark","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Romark \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Undisclosed"},{"orgOrder":0,"company":"Synermore Biologics","sponsor":"Simoon Record Pharma Information Consulting Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SYN023","moa":"Rabies virus glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Synermore Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Synermore Biologics \/ Simoon Record Pharma Information Consulting Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Synermore Biologics \/ Simoon Record Pharma Information Consulting Co., Ltd."},{"orgOrder":0,"company":"Henan Genuine Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Henan Genuine Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Henan Genuine Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Henan Genuine Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Henan Normal University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Henan Normal University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Henan Normal University \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Henan Normal University \/ Undisclosed"},{"orgOrder":0,"company":"HRH Pharmaceuticals","sponsor":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil | UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE, Brazil","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HRH Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HRH Pharmaceuticals \/ GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil | UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE, Brazil","highestDevelopmentStatusID":"10","companyTruncated":"HRH Pharmaceuticals \/ GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil | UNIVERSIDADE ESTADUAL DO NORTE FLUMINENSE, Brazil"},{"orgOrder":0,"company":"HRH Pharmaceuticals","sponsor":"GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil | Clinical Research Unit \/ High Complexity Center (CRU\/HCC) \/ Galzu Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HRH Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HRH Pharmaceuticals \/ GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil | Clinical Research Unit \/ High Complexity Center (CRU\/HCC) \/ Galzu Institute","highestDevelopmentStatusID":"10","companyTruncated":"HRH Pharmaceuticals \/ GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil | Clinical Research Unit \/ High Complexity Center (CRU\/HCC) \/ Galzu Institute"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Tigermed"},{"orgOrder":0,"company":"LAXAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"||RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LAXAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LAXAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LAXAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"CMIC Holdings","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CMIC Holdings","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CMIC Holdings \/ Fujifilm holding","highestDevelopmentStatusID":"10","companyTruncated":"CMIC Holdings \/ Fujifilm holding"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Hisun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhejiang Hisun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zhejiang Hisun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhejiang Hisun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chelsea and Westminster NHS Trust","sponsor":"NEAT ID Foundation | Fujifilm Toyama Chemical | Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chelsea and Westminster NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chelsea and Westminster NHS Trust \/ NEAT ID Foundation | Fujifilm Toyama Chemical | Imperial College London","highestDevelopmentStatusID":"10","companyTruncated":"Chelsea and Westminster NHS Trust \/ NEAT ID Foundation | Fujifilm Toyama Chemical | Imperial College London"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"R-Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"R-Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Carelink","sponsor":"Fujifilm holding","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Carelink","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Carelink \/ Fujifilm holding","highestDevelopmentStatusID":"10","companyTruncated":"Carelink \/ Fujifilm holding"},{"orgOrder":0,"company":"RAAS Nutritionals, LLC","sponsor":"Kayseri City Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RAAS Nutritionals, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RAAS Nutritionals, LLC \/ Kayseri City Hospital","highestDevelopmentStatusID":"10","companyTruncated":"RAAS Nutritionals, LLC \/ Kayseri City Hospital"},{"orgOrder":0,"company":"Promomed","sponsor":"Solyur Pharmaceuticals Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Promomed \/ Solyur Pharmaceuticals Group","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Solyur Pharmaceuticals Group"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Gilead Sciences"},{"orgOrder":0,"company":"Inserm","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ World Health Organization","highestDevelopmentStatusID":"10","companyTruncated":"Inserm \/ World Health Organization"},{"orgOrder":0,"company":"UCI Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"UCI Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"UCI Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"UCI Health \/ Undisclosed"},{"orgOrder":0,"company":"Montefiore Health System","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"||RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montefiore Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Montefiore Health System \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Montefiore Health System \/ National Institutes of Health"},{"orgOrder":0,"company":"Evergreenhealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evergreenhealth","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evergreenhealth \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evergreenhealth \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | US Department of Veterans Affairs"},{"orgOrder":0,"company":"Feinstein Institutes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Feinstein Institutes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Feinstein Institutes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Feinstein Institutes \/ Undisclosed"},{"orgOrder":0,"company":"FHI Clinical","sponsor":"Leidos Biomedical Research, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"FHI Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FHI Clinical \/ Leidos Biomedical Research, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"FHI Clinical \/ Leidos Biomedical Research, Inc."},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.RSV.preF Vaccine","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1345","moa":"RSV F","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Medicines for Malaria Venture","sponsor":"Shin Poong Pharm Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pyronaridine","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase (ATP2A)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicines for Malaria Venture","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Medicines for Malaria Venture \/ Shin Poong Pharm Co Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Medicines for Malaria Venture \/ Shin Poong Pharm Co Ltd"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS||Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS||Virus RNA-dependent RNA polymerase (Viru RdRP)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Atea Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Atea Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Atea Pharmaceuticals"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series D Financing","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.22,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34999999999999998,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atea Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bemnifosbuvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Atea Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atea Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Atea Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensitrelvir","moa":"3CLpro||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ensitrelvir","moa":"3CLpro||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Ping An-Shionogi","sponsor":"Chia Tai Tianqing Pharmaceutical Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Ensitrelvir Fumaric Acid","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ping An-Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ping An-Shionogi \/ Chia Tai Tianqing Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Ping An-Shionogi \/ Chia Tai Tianqing Pharmaceutical Group"},{"orgOrder":0,"company":"The AIDS Clinical Trials Group","sponsor":"Shionogi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensitrelvir Fumaric Acid","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"The AIDS Clinical Trials Group \/ Shionogi","highestDevelopmentStatusID":"10","companyTruncated":"The AIDS Clinical Trials Group \/ Shionogi"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuzatrelvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibuzatrelvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obeldesivir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obeldesivir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obeldesivir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olgotrelvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Olgotrelvir","moa":"SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sorrento Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Health Canada | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"3CLpro||SARS coronavirus 3C-like proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Health Canada | Canadian Institutes of Health Research","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Health Canada | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Promomed","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nirmatrelvir","moa":"SARS coronavirus 3C-like proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Promomed \/ Sponsor GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Sponsor GmbH"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lufotrelvir","moa":"3CLpro||SARS||SARS","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"Biological E","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biological E","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biological E \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Biological E \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grand River Aseptic Manufacturing","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Grand River Aseptic Manufacturing \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Grand River Aseptic Manufacturing \/ Johnson & Johnson"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ Undisclosed"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Sinovac Biotech"},{"orgOrder":0,"company":"Hipra Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hipra Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hipra Scientific \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hipra Scientific \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ GSK"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharm-Olam \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam \/ US Department of Defense"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Monash University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Monash University","highestDevelopmentStatusID":"10","companyTruncated":"Bayside Health \/ Monash University"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SARs-CoV-2 antigen","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Sipavibart","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"RQ Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Sipavibart","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ RQ Bio","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ RQ Bio"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Diagn\u00f3sticos da Am\u00e9rica S\/A","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Diagn\u00f3sticos da Am\u00e9rica S\/A","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Diagn\u00f3sticos da Am\u00e9rica S\/A"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ CEPI"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University Of Nebraska Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ University Of Nebraska Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ University Of Nebraska Medical Center"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":2.7999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":2.7999999999999998,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Undisclosed"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"United Biomedical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ United Biomedical","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ United Biomedical"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"Ministry Of Health And Welfare, Taiwan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"UB-612","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxxinity","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Vaxxinity \/ Ministry Of Health And Welfare, Taiwan","highestDevelopmentStatusID":"10","companyTruncated":"Vaxxinity \/ Ministry Of Health And Welfare, Taiwan"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QLS1128","moa":"SARS-CoV-2 3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"QLS1128","moa":"SARS-CoV-2 3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"QLS1128","moa":"SARS-CoV-2 3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qilu Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Vinnerna Biosciences Co., Ltd.","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JT001","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Vinnerna Biosciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Vinnerna Biosciences Co., Ltd. \/ Sponsor GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Vinnerna Biosciences Co., Ltd. \/ Sponsor GmbH"},{"orgOrder":0,"company":"Shanghai Vinnerna Biosciences Co., Ltd.","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JT001","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Vinnerna Biosciences Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai Vinnerna Biosciences Co., Ltd. \/ Sponsor GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Vinnerna Biosciences Co., Ltd. \/ Sponsor GmbH"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JT001","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radboud University Medical Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Radboud University Medical Centre","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Radboud University Medical Centre"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Radhoud University Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Radhoud University Medical","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Radhoud University Medical"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Danish Ministry of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Danish Ministry of Health","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Danish Ministry of Health"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ABNCoV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Undisclosed"},{"orgOrder":0,"company":"Petrovax","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Petrovax \/ CanSino Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/ CanSino Biologics"},{"orgOrder":0,"company":"Botswana Harvard AIDS Institute Partnership","sponsor":"AstraZeneca | Botswana Ministry of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BOTSWANA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Botswana Harvard AIDS Institute Partnership","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Botswana Harvard AIDS Institute Partnership \/ AstraZeneca | Botswana Ministry of Health","highestDevelopmentStatusID":"10","companyTruncated":"Botswana Harvard AIDS Institute Partnership \/ AstraZeneca | Botswana Ministry of Health"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Medicago","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ Undisclosed"},{"orgOrder":0,"company":"Medicago","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ National Institutes of Health"},{"orgOrder":0,"company":"Medicago","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Coronavirus Virus-Like Particle COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ CureVac"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Termination","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ CureVac"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hetero Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Tibet Rhodiola Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tibet Rhodiola Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tibet Rhodiola Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tibet Rhodiola Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Hetero Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hetero Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hetero Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hetero Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Siberian Vector institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Siberian Vector institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Siberian Vector institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Siberian Vector institute \/ Undisclosed"},{"orgOrder":0,"company":"Uniao Quimica Farmaceutica Nacional","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Uniao Quimica Farmaceutica Nacional","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniao Quimica Farmaceutica Nacional \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Uniao Quimica Farmaceutica Nacional \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Moscow Government | Crocus Medical BV","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Moscow Government | Crocus Medical BV","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Moscow Government | Crocus Medical BV"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Russian Direct Investment Fund | iPharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Russian Direct Investment Fund | iPharma","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Russian Direct Investment Fund | iPharma"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"International Vaccine Institute | GSK | Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ International Vaccine Institute | GSK | Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ International Vaccine Institute | GSK | Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations | International Vaccine Institute | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | International Vaccine Institute | GSK","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | International Vaccine Institute | GSK"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ CEPI"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ GSK"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Coalition for Epidemic Preparedness Innovations | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GBP510","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | GSK","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Coalition for Epidemic Preparedness Innovations | GSK"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"HDT Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ HDT Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ HDT Biotech"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HGCO19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Gennova Biopharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"G42 Healthcare | Abu Dhabi Health Services Company | Wuhan Institute of Biological Products | Beijing Institute of Biological Products Co Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ G42 Healthcare | Abu Dhabi Health Services Company | Wuhan Institute of Biological Products | Beijing Institute of Biological Products Co Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ G42 Healthcare | Abu Dhabi Health Services Company | Wuhan Institute of Biological Products | Beijing Institute of Biological Products Co Ltd."},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ Universitas Padjadjaran | NIHRD, Ministry of Health, Indonesia | Sinovac Biotech"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Beijing Institute of Biological Products Co Ltd. | China National Biotec Group | Fundaci\u00f3n Hu\u00e9sped","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorio Elea Phoenix \/ Beijing Institute of Biological Products Co Ltd. | China National Biotec Group | Fundaci\u00f3n Hu\u00e9sped","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorio Elea Phoenix \/ Beijing Institute of Biological Products Co Ltd. | China National Biotec Group | Fundaci\u00f3n Hu\u00e9sped"},{"orgOrder":0,"company":"Pontificia Universidad Catolica de Chile","sponsor":"Ministry of Health, Chile | Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHILE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pontificia Universidad Catolica de Chile","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pontificia Universidad Catolica de Chile \/ Ministry of Health, Chile | Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Pontificia Universidad Catolica de Chile \/ Ministry of Health, Chile | Sinovac Biotech"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.214","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"The Translational Health Science and Technology Institute","sponsor":"Nanogen Pharmaceutical Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Nanocovax","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"The Translational Health Science and Technology Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"The Translational Health Science and Technology Institute \/ Nanogen Pharmaceutical Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"The Translational Health Science and Technology Institute \/ Nanogen Pharmaceutical Biotechnology"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Nanocovax","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Nanocovax","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Cogna Technology Solutions","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"NVX-CoV2373","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cogna Technology Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cogna Technology Solutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Cogna Technology Solutions \/ Novavax"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ BARDA"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ CSL Behring"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Termination","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ US Department of Defense"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Big Cypress Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Merger","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Big Cypress Acquisition Corp","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Big Cypress Acquisition Corp"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ BARDA"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Funding","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"SAB Biotherapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ BARDA"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Department of Health and Human Services | JPEO CBRND Enabling Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"SAB Biotherapeutics \/ Department of Health and Human Services | JPEO CBRND Enabling Biotechnologies","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Department of Health and Human Services | JPEO CBRND Enabling Biotechnologies"},{"orgOrder":0,"company":"SAB Biotherapeutics","sponsor":"Biomedical Advanced Research and Development Authority | JPEO CBRND Enabling Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SAB Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"SAB Biotherapeutics \/ Biomedical Advanced Research and Development Authority | JPEO CBRND Enabling Biotechnologies","highestDevelopmentStatusID":"10","companyTruncated":"SAB Biotherapeutics \/ Biomedical Advanced Research and Development Authority | JPEO CBRND Enabling Biotechnologies"},{"orgOrder":0,"company":"Bayer AG","sponsor":"CureVac","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bayer AG \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Bayer AG \/ CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"CureVac \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ GSK"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ BofA Securities"},{"orgOrder":0,"company":"CureVac","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ European Investment Bank"},{"orgOrder":0,"company":"CureVac","sponsor":"German Federal Ministry Of Education And Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.29999999999999999,"dosageForm":"Injection","sponsorNew":"CureVac \/ German Federal Ministry Of Education And Research","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ German Federal Ministry Of Education And Research"},{"orgOrder":0,"company":"CureVac","sponsor":"Tesla","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Tesla","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Tesla"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ University Medical Center"},{"orgOrder":0,"company":"Celonic","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celonic \/ CureVac","highestDevelopmentStatusID":"10","companyTruncated":"Celonic \/ CureVac"},{"orgOrder":0,"company":"CureVac","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Bayer AG"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"European Commission","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ European Commission","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ European Commission"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Wacker Chemie AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CVnCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Wacker Chemie AG","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Wacker Chemie AG"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Suzhou Abogen Biosciences | Walvax Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Walvax Biotechnology \/ Suzhou Abogen Biosciences | Walvax Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Suzhou Abogen Biosciences | Walvax Biotechnology"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 mRNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Walvax Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS03","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Recombinant Protein Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Dr. Soetomo General Hospital","sponsor":"Indonesia Ministry of Health | Universitas Airlangga | Bioxis Pharmaceuticalls","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Soetomo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | Bioxis Pharmaceuticalls","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | Bioxis Pharmaceuticalls"},{"orgOrder":0,"company":"Dr. Soetomo General Hospital","sponsor":"Indonesia Ministry of Health | Universitas Airlangga | Bioxis Pharmaceuticalls","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Soetomo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | Bioxis Pharmaceuticalls","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | Bioxis Pharmaceuticalls"},{"orgOrder":0,"company":"Codagenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Undisclosed"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Codagenix","sponsor":"US Department Of Health And Human Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Codagenix \/ US Department Of Health And Human Services","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ US Department Of Health And Human Services"},{"orgOrder":0,"company":"Codagenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Undisclosed"},{"orgOrder":0,"company":"Codagenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Undisclosed"},{"orgOrder":0,"company":"Codagenix","sponsor":"Serum Institute of India","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Serum Institute of India"},{"orgOrder":0,"company":"Codagenix","sponsor":"Univercells","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Codagenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Codagenix \/ Univercells","highestDevelopmentStatusID":"10","companyTruncated":"Codagenix \/ Univercells"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"TAK-019","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"TAK-019","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of Liege","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, mRNA","moa":"SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Liege","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Liege \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"University of Liege \/ Pfizer Inc"},{"orgOrder":0,"company":"Tychan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Undisclosed"},{"orgOrder":0,"company":"Tychan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Undisclosed"},{"orgOrder":0,"company":"Tychan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Undisclosed"},{"orgOrder":0,"company":"Tychan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TY027","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tychan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tychan \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tychan \/ Undisclosed"},{"orgOrder":0,"company":"Pharm-Olam","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"VLA2001","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm-Olam","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharm-Olam \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharm-Olam \/ Undisclosed"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Ocugen","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole-Virion Inactivated SARS-CoV-2 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ocugen \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Bharat Biotech"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole-virus Inactivated SARS-CoV-2 Vaccine, Adjuvanted","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Cellid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AdCLD-CoV19-1 OMI","moa":"SARS-CoV-2 S (Omicron)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cellid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cellid \/ Undisclosed"},{"orgOrder":0,"company":"Cellid","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AdCLD-CoV19-1 OMI","moa":"SARS-CoV-2 S (Omicron)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cellid","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellid \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cellid \/ Undisclosed"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"DNA Vaccine Recombinant","moa":"SARS-CoV-2 S1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaJet \/ Undisclosed"},{"orgOrder":0,"company":"University College London Hospitals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University College London Hospitals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University College London Hospitals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"University College London Hospitals \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Parexel"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.48999999999999999,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ BARDA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Care Access Research","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Care Access Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Care Access Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Care Access Research \/ AstraZeneca"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lenvervimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Monovalent D614","moa":"SARS-CoV-2 spike protein (D614)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Camostatum","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nafamostat","moa":"Serine protease||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chong Kun Dang Pharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chong Kun Dang Pharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chong Kun Dang Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Verrica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Serine\/threonine PP1-alpha (PPP1CA)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film-Forming Solution","sponsorNew":"Torii Pharmaceutical \/ Verrica Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Verrica Pharmaceuticals"},{"orgOrder":0,"company":"resTORbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dactolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio \/ Undisclosed"},{"orgOrder":0,"company":"resTORbio","sponsor":"National Institute on Aging","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Dactolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"resTORbio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"resTORbio \/ National Institute on Aging","highestDevelopmentStatusID":"10","companyTruncated":"resTORbio \/ National Institute on Aging"},{"orgOrder":0,"company":"TrialSpark","sponsor":"resTORbio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Dactolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TrialSpark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TrialSpark \/ resTORbio","highestDevelopmentStatusID":"10","companyTruncated":"TrialSpark \/ resTORbio"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dactolisib","moa":"Serine\/threonine-protein kinase mTOR | PI3-kinase class I","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adicet Bio \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Adicet Bio \/ Undisclosed"},{"orgOrder":0,"company":"Octapharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aripiprazole Lauroxil","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor | Dopamine D2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"RedHill Biopharma \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"Genuine Research Center, Egypt","sponsor":"ADWIA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genuine Research Center, Egypt","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genuine Research Center, Egypt \/ ADWIA Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Genuine Research Center, Egypt \/ ADWIA Pharma"},{"orgOrder":0,"company":"Cytel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Serotonin transporter","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cytel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cytel \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cytel \/ Undisclosed"},{"orgOrder":0,"company":"San Diego Veterans Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bismuth","moa":"Serum albumin (ALB)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"San Diego Veterans Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"San Diego Veterans Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"San Diego Veterans Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Saint Luke's Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Saint Luke's Health System","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Saint Luke's Health System"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Saint Luke\u2019s Health System","sponsor":"St. Luke's Hospital, Kansas City | AstraZeneca | George Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Saint Luke\u2019s Health System","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saint Luke\u2019s Health System \/ St. Luke's Hospital, Kansas City | AstraZeneca | George Clinical","highestDevelopmentStatusID":"10","companyTruncated":"Saint Luke\u2019s Health System \/ St. Luke's Hospital, Kansas City | AstraZeneca | George Clinical"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fosphenytoin Sodium","moa":"Sodium channel alpha subunit||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Pulse Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Pulse Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bellerophon Pulse Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Pulse Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bellerophon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bellerophon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Bellerophon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bellerophon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Beyond Air","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Nitric Oxide","moa":"||Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beyond Air","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Beyond Air \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Beyond Air \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"SaNOtize","sponsor":"The Emmes Company, LLC | Keyrus Life Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ The Emmes Company, LLC | Keyrus Life Science","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ The Emmes Company, LLC | Keyrus Life Science"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Horizons Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Horizons Ventures","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Horizons Ventures"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Amubarvimab","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Eli Lilly"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BRII-196","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Casirivimab","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, mRNA","moa":"Spike glycoprotein||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Swiss Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Swiss Government","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Swiss Government"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ J.P. Morgan"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Molecular Partners","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.23000000000000001,"dosageForm":"Infusion","sponsorNew":"Molecular Partners \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Molecular Partners \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"AbCellera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbCellera \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AbCellera \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ AbCellera","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ AbCellera"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eli Lilly \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Amgen Inc"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"AbCellera | Shanghai Junshi Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ AbCellera | Shanghai Junshi Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ AbCellera | Shanghai Junshi Biosciences"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"LY3819253","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MP0420","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Recipharm AB","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"TAK-919","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Recipharm AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Recipharm AB \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Recipharm AB \/ Moderna Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"TAK-919","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Moderna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Moderna Therapeutics"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Mycophenolate Mofetil","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"MediMergent, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tixagevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MediMergent, LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MediMergent, LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MediMergent, LLC \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"CareDx","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CareDx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CareDx \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CareDx \/ Vir Biotechnology"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ International Network for Strategic Initiatives in Global HIV Trials | University of Copenhagen | Medical Research Council | Kirby Institute | Washington D.C. VA Medical Center | Advancing Clinical Therapeutics Globally | National Heart, Lung, and Blood I"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MOB015B","moa":"Squalene epoxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Biorasi"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Biorasi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Biorasi"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"GHS Investments","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Financing","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ GHS Investments","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ GHS Investments"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Therapeutic Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor","sponsor":"Monitor CRO | Exeltis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fenticonazole Nitrate","moa":"sterol","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor \/ Monitor CRO | Exeltis","highestDevelopmentStatusID":"10","companyTruncated":"Fundaci\u00f3n para la Investigaci\u00f3n e Innovaci\u00f3n Biom\u00e9dica del Hospital Universitario Infanta Leonor \/ Monitor CRO | Exeltis"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Hetero Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Hetero Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Hetero Biopharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Emcure Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Emcure Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Emcure Pharmaceuticals"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Eva Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Eva Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Eva Pharma"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Ferozsons Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Ferozsons Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Ferozsons Laboratories"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Viatris"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Lenacapavir","moa":"Structural capsid protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Evolocumab","moa":"Subtilisin\/kexin type 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"VBI Vaccines","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"Hepatitis B Vaccine","moa":"Surface antigen (HBsAg)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"VBI Vaccines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"VBI Vaccines \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"VBI Vaccines \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Pulmocide","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Opelconazole","moa":"systemic antifungals (miconazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Pulmocide \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pulmocide \/ Undisclosed"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Opelconazole","moa":"systemic antifungals (miconazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Pulmocide \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opelconazole","moa":"systemic antifungals (miconazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmocide","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pulmocide \/ Undisclosed"},{"orgOrder":0,"company":"Pulmocide","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Opelconazole","moa":"systemic antifungals (miconazole type)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pulmocide","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Suspension for Inhalation","sponsorNew":"Pulmocide \/ Jeito Capital","highestDevelopmentStatusID":"10","companyTruncated":"Pulmocide \/ Jeito Capital"},{"orgOrder":0,"company":"Equillium","sponsor":"Biocon","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Itolizumab","moa":"T-cell differentiation antigen CD6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Equillium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Equillium \/ Biocon","highestDevelopmentStatusID":"10","companyTruncated":"Equillium \/ Biocon"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ J.P. Morgan"},{"orgOrder":0,"company":"AlloVir","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Kite Pharma","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Kite Pharma"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Undisclosed"},{"orgOrder":0,"company":"AlloVir","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"Posoleucel","moa":"T-cell receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AlloVir","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.28000000000000003,"dosageForm":"Infusion","sponsorNew":"AlloVir \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"AlloVir \/ Morgan Stanley"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"||T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung Veterans General Hospital. | Taoyuan General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United BioPharma \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung Veterans General Hospital. | Taoyuan General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung Veterans General Hospital. | Taoyuan General Hospital"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Chidamide","moa":"||T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"UB-421","moa":"T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GR2001","moa":"Tetanus toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"GR2001","moa":"Tetanus toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Gyre Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hydronidone","moa":"TGF-beta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gyre Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gyre Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gyre Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Amgen Inc"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Fortrea","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Fortrea"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Tezepelumab","moa":"Thymic stromal lymphopoietin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Duke University","sponsor":"National Institute of Allergy and Infectious Diseases | Pham Ngoc Thach University of Medicine | Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | National Hospital for Tropical Diseases, Hanoi | Bach Mai Hospital | Gilead Sciences | Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fluocytosine","moa":"Thymidylate synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ National Institute of Allergy and Infectious Diseases | Pham Ngoc Thach University of Medicine | Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | National Hospital for Tropical Diseases, Hanoi | Bach Mai Hospital | Gilead Sciences | Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Duke University \/ National Institute of Allergy and Infectious Diseases | Pham Ngoc Thach University of Medicine | Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam | National Hospital for Tropical Diseases, Hanoi | Bach Mai Hospital | Gilead Sciences | Viatris"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Abatacept","moa":"||T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"||TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Resilience Government Services","sponsor":"Pharm-Olam | CBRN Medical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Resilience Government Services","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Resilience Government Services \/ Pharm-Olam | CBRN Medical","highestDevelopmentStatusID":"10","companyTruncated":"Resilience Government Services \/ Pharm-Olam | CBRN Medical"},{"orgOrder":0,"company":"Cardresearch","sponsor":"Cardresearch | Cytel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cardresearch","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cardresearch \/ Cardresearch | Cytel","highestDevelopmentStatusID":"10","companyTruncated":"Cardresearch \/ Cardresearch | Cytel"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"German Center for Diabetes Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 7 | Ferriprotoporphyrin IX | Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apsen Farmaceutica \/ German Center for Diabetes Research","highestDevelopmentStatusID":"10","companyTruncated":"Apsen Farmaceutica \/ German Center for Diabetes Research"},{"orgOrder":0,"company":"Abderrahmane Mami Hospital","sponsor":"Gangnam Severance Hospital | Datametrix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TUNISIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Abderrahmane Mami Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix","highestDevelopmentStatusID":"10","companyTruncated":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix"},{"orgOrder":0,"company":"Abderrahmane Mami Hospital","sponsor":"Gangnam Severance Hospital | Datametrix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TUNISIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Abderrahmane Mami Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix","highestDevelopmentStatusID":"10","companyTruncated":"Abderrahmane Mami Hospital \/ Gangnam Severance Hospital | Datametrix"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Institut Pasteur","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Institut Pasteur","highestDevelopmentStatusID":"10","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Institut Pasteur"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang","highestDevelopmentStatusID":"10","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang"},{"orgOrder":0,"company":"Fundaci\u00f3n FLS","sponsor":"Germans Trias i Pujol Hospital | Department of Health, Catalonia | Gebro Pharma | Rubio Laboratories | Institut Catal\u00e0 de Salut","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fundaci\u00f3n FLS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fundaci\u00f3n FLS \/ Germans Trias i Pujol Hospital | Department of Health, Catalonia | Gebro Pharma | Rubio Laboratories | Institut Catal\u00e0 de Salut","highestDevelopmentStatusID":"10","companyTruncated":"Fundaci\u00f3n FLS \/ Germans Trias i Pujol Hospital | Department of Health, Catalonia | Gebro Pharma | Rubio Laboratories | Institut Catal\u00e0 de Salut"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"University of Manitoba | University of Alberta | University of British Columbia | McMaster University | London Health Sciences Centre Research Institute (Lawson) | Eastern Health | University of Minnesota","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McGill University Health Centre Research Institute \/ University of Manitoba | University of Alberta | University of British Columbia | McMaster University | London Health Sciences Centre Research Institute (Lawson) | Eastern Health | University of Minnesota","highestDevelopmentStatusID":"10","companyTruncated":"McGill University Health Centre Research Institute \/ University of Manitoba | University of Alberta | University of British Columbia | McMaster University | London Health Sciences Centre Research Institute (Lawson) | Eastern Health | University of Minnesota"},{"orgOrder":0,"company":"LSU Health Sciences Center New Orleans","sponsor":"Lafayette General Health | University of Louisiana at Lafayette","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LSU Health Sciences Center New Orleans","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LSU Health Sciences Center New Orleans \/ Lafayette General Health | University of Louisiana at Lafayette","highestDevelopmentStatusID":"10","companyTruncated":"LSU Health Sciences Center New Orleans \/ Lafayette General Health | University of Louisiana at Lafayette"},{"orgOrder":0,"company":"LCMC Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LCMC Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"LCMC Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LCMC Health \/ Undisclosed"},{"orgOrder":0,"company":"Sanford Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanford Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanford Health \/ Undisclosed"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah | Utah Department of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ University of Utah | Utah Department of Health","highestDevelopmentStatusID":"10","companyTruncated":"Intermountain Health \/ University of Utah | Utah Department of Health"},{"orgOrder":0,"company":"Intermountain Health","sponsor":"University of Utah","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intermountain Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intermountain Health \/ University of Utah","highestDevelopmentStatusID":"10","companyTruncated":"Intermountain Health \/ University of Utah"},{"orgOrder":0,"company":"Hospital do Coracao","sponsor":"Hospital Israelita Albert Einstein | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network | EMS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital do Coracao","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital do Coracao \/ Hospital Israelita Albert Einstein | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network | EMS","highestDevelopmentStatusID":"10","companyTruncated":"Hospital do Coracao \/ Hospital Israelita Albert Einstein | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network | EMS"},{"orgOrder":0,"company":"Hospital Israelita Albert Einstein","sponsor":"EMS | Hospital do Coracao | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hospital Israelita Albert Einstein","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Israelita Albert Einstein \/ EMS | Hospital do Coracao | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network","highestDevelopmentStatusID":"10","companyTruncated":"Hospital Israelita Albert Einstein \/ EMS | Hospital do Coracao | Hospital Sirio-Libanes | Brazilian Research In Intensive Care Network"},{"orgOrder":0,"company":"Salomeh Keyhani MD","sponsor":"San Francisco VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Salomeh Keyhani MD","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Salomeh Keyhani MD \/ San Francisco VA Health Care System","highestDevelopmentStatusID":"10","companyTruncated":"Salomeh Keyhani MD \/ San Francisco VA Health Care System"},{"orgOrder":0,"company":"Dr. Michael Hill","sponsor":"Alberta Health services | University of Alberta | University of Calgary | Calgary Health Trust | Alberta Innovates Health Solutions | Government of Alberta","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Michael Hill","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Michael Hill \/ Alberta Health services | University of Alberta | University of Calgary | Calgary Health Trust | Alberta Innovates Health Solutions | Government of Alberta","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Michael Hill \/ Alberta Health services | University of Alberta | University of Calgary | Calgary Health Trust | Alberta Innovates Health Solutions | Government of Alberta"},{"orgOrder":0,"company":"University Hospitals Geneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospitals Geneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospitals Geneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"University Hospitals Geneva \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Duke Clinical Research Institute","sponsor":"Pcori","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Duke Clinical Research Institute","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Duke Clinical Research Institute \/ Pcori","highestDevelopmentStatusID":"10","companyTruncated":"Duke Clinical Research Institute \/ Pcori"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"World Health Organization","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"World Health Organization","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"World Health Organization \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"World Health Organization \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Topoisomerase IV | Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Gepotidacin","moa":"Topoisomerase IV | Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Veru","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sabizabulin","moa":"TUBB","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Veru \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"National Heart, Lung, and Blood Institute | Bill & Melinda Gates Foundation | The Government of Quebec | Dacima Software Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ National Heart, Lung, and Blood Institute | Bill & Melinda Gates Foundation | The Government of Quebec | Dacima Software Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ National Heart, Lung, and Blood Institute | Bill & Melinda Gates Foundation | The Government of Quebec | Dacima Software Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Montreal Heart Institute \/ Pharmascience Inc."},{"orgOrder":0,"company":"Population Health Research Institute","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Population Health Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Population Health Research Institute \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Population Health Research Institute \/ Bayer AG"},{"orgOrder":0,"company":"NYU Grossman School of Medicine","sponsor":"Montreal Heart Institute Research Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NYU Grossman School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Grossman School of Medicine \/ Montreal Heart Institute Research Center","highestDevelopmentStatusID":"10","companyTruncated":"NYU Grossman School of Medicine \/ Montreal Heart Institute Research Center"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"BeyondSpring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Plinabulin","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BeyondSpring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeyondSpring \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BeyondSpring \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Peginterferon Lambda","moa":"Type III IFN receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eiger BioPharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"University of Wisconsin School of Medicine","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Wisconsin School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Wisconsin School of Medicine \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"University of Wisconsin School of Medicine \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Incepta Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incepta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incepta Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Incepta Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baricitinib","moa":"Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BenevolentAI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BenevolentAI \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baricitinib","moa":"||Tyrosine-protein kinase JAK2 | Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pacritinib","moa":"Tyrosine-protein kinase receptor FLT3 | Tyrosine-protein kinase JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CTI BioPharma Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CTI BioPharma Corp \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Funding","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rigel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rigel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"MJM Bonten","sponsor":"ZonMw | Saltro","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Fosfomycin Trometamol","moa":"UDP-N-acetylglucosamine 1-carboxyvinyltransferase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MJM Bonten","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"MJM Bonten \/ ZonMw | Saltro","highestDevelopmentStatusID":"10","companyTruncated":"MJM Bonten \/ ZonMw | Saltro"},{"orgOrder":0,"company":"Shanghai Zerun Biotech","sponsor":"Yuxi Zerun Biotechnology Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Human Papillomavirus Bivalent (Types 16, 18) Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Zerun Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Zerun Biotech \/ Yuxi Zerun Biotechnology Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Zerun Biotech \/ Yuxi Zerun Biotechnology Co., Ltd."},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Guangxi Center for Disease Control and Prevention | Henan Center for Disease Control and Prevention | Sichuan Center for Disease Control and Prevention | Shanxi Center for Disease Control and Prevention | Yunnan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Human Papillomavirus 14-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Guangxi Center for Disease Control and Prevention | Henan Center for Disease Control and Prevention | Sichuan Center for Disease Control and Prevention | Shanxi Center for Disease Control and Prevention | Yunnan Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Guangxi Center for Disease Control and Prevention | Henan Center for Disease Control and Prevention | Sichuan Center for Disease Control and Prevention | Shanxi Center for Disease Control and Prevention | Yunnan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SCTV01C","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SCTV01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SCTV01E","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Andrographis Paniculata","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Westlake Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"WPV01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Westlake Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Westlake Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Westlake Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Westlake Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"WPV01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Westlake Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Westlake Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Westlake Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Trinomab Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TNM001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhuhai Trinomab Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Trinomab Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TNM001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhuhai Trinomab Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Trinomab Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TNM001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhuhai Trinomab Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Trinomab Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TNM002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhuhai Trinomab Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Trinomab Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TNM002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhuhai Trinomab Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhuhai Trinomab Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TNM002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zhuhai Trinomab Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zhuhai Trinomab Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valneva \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Pfizer Inc"},{"orgOrder":0,"company":"Walvax Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"13-Valent Pneumococcal Polysaccharide Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Walvax Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Walvax Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Walvax Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"13-valent Pneumococcal Polysaccharide Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"15-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"20vPnC","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"21-valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"21-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ligand Pharmaceuticals \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Ligand Pharmaceuticals \/ Merck & Co"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"5-Valent Meningococcal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bovax Biotechnology Co., Ltd.","sponsor":"Chongqing Bovax Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Bovax Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Bovax Biotechnology Co., Ltd. \/ Chongqing Bovax Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Bovax Biotechnology Co., Ltd. \/ Chongqing Bovax Biopharmaceutical"},{"orgOrder":0,"company":"Shanghai Bovax Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Bovax Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Bovax Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Bovax Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-valent HPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9-Valent HPV Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Recbio Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Recbio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"9vHPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.COV2.S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ad26.Mos4.HIV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.ZEBOV","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Ad26.ZEBOV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad26-based RSV preF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC-189","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Jiaxing AnDiCon Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ADC-189","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiaxing AnDiCon Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiaxing AnDiCon Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiaxing AnDiCon Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Adjuvanted Quadrivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Adjuvanted Recombinant Spike Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute"},{"orgOrder":0,"company":"Insmed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ALIS","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Insmed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Antiwei","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Apo-Hydroxychloroquine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aqiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Seqirus | Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ARCT-2303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arcturus Therapeutics \/ Seqirus | Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Arcturus Therapeutics \/ Seqirus | Novotech"},{"orgOrder":0,"company":"Universidad de Antioquia","sponsor":"Innovation Corporation for the Development of Products for Tropical Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"COLOMBIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Arnica","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Universidad de Antioquia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Universidad de Antioquia \/ Innovation Corporation for the Development of Products for Tropical Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Universidad de Antioquia \/ Innovation Corporation for the Development of Products for Tropical Diseases"},{"orgOrder":0,"company":"Universidad de Antioquia","sponsor":"Innovation Corporation for the Development of Products for Tropical Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"COLOMBIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Arnica","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Universidad de Antioquia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Universidad de Antioquia \/ Innovation Corporation for the Development of Products for Tropical Diseases","highestDevelopmentStatusID":"10","companyTruncated":"Universidad de Antioquia \/ Innovation Corporation for the Development of Products for Tropical Diseases"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AV5080","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AV5080","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Icon Plc","sponsor":"BARDA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Icon Plc \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Icon Plc \/ BARDA"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AV7909","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"ZonMw | Stichting Hemato-Oncologie voor Volwassenen Nederland","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Azole","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw | Stichting Hemato-Oncologie voor Volwassenen Nederland","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ ZonMw | Stichting Hemato-Oncologie voor Volwassenen Nederland"},{"orgOrder":0,"company":"Inmunotek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bacmune","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Inmunotek \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ Undisclosed"},{"orgOrder":0,"company":"Inmunotek","sponsor":"BioClever 2005","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bactek-MV130","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Inmunotek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Inmunotek \/ BioClever 2005","highestDevelopmentStatusID":"10","companyTruncated":"Inmunotek \/ BioClever 2005"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BBV154 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Drops","sponsorNew":"Bharat Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Undisclosed"},{"orgOrder":0,"company":"TASK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TASK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"TASK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TASK \/ Undisclosed"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"University of Southern Denmark","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG-Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bandim Health Project \/ University of Southern Denmark","highestDevelopmentStatusID":"10","companyTruncated":"Bandim Health Project \/ University of Southern Denmark"},{"orgOrder":0,"company":"Bandim Health Project","sponsor":"Odense Patient Data Explorative Network | Odense University Hospital | Municipality of Odense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GUINEA-BISSAU","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BCG-Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bandim Health Project","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bandim Health Project \/ Odense Patient Data Explorative Network | Odense University Hospital | Municipality of Odense","highestDevelopmentStatusID":"10","companyTruncated":"Bandim Health Project \/ Odense Patient Data Explorative Network | Odense University Hospital | Municipality of Odense"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Bivalent Inactivated Enterovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Bivalent Inactivated Enterovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bivalent Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"pH-D Feminine Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Boric Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"pH-D Feminine Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"pH-D Feminine Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"pH-D Feminine Health \/ Undisclosed"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BR-TD-1001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Biotest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BT097","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biotest \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Candidate Varicella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cell-Derived Quadrivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ Emergent BioSolutions","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Emergent BioSolutions"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"CHIKV VLP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"International Vaccine Institute","sponsor":"EuBiologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Cholera Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Vaccine Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"International Vaccine Institute \/ EuBiologics","highestDevelopmentStatusID":"10","companyTruncated":"International Vaccine Institute \/ EuBiologics"},{"orgOrder":0,"company":"MGC Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CimetrA-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MGC Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGC Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MGC Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CinnaGen COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute Ltd | CinnaGen"},{"orgOrder":0,"company":"Vaxine","sponsor":"Australian Respiratory and Sleep Medicine Institute | CinnaGen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CinnaGen COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vaxine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute | CinnaGen","highestDevelopmentStatusID":"10","companyTruncated":"Vaxine \/ Australian Respiratory and Sleep Medicine Institute | CinnaGen"},{"orgOrder":0,"company":"Colgate Palmolive","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Colgate Total Clean Mint","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Colgate Palmolive","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Paste","sponsorNew":"Colgate Palmolive \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Colgate Palmolive \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Human Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ National Institutes of Health"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University","highestDevelopmentStatusID":"10","companyTruncated":"Bio Farma \/ University of Indonesia | Diponegoro University | Andalas University | Hasanuddin University"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine (Inactivated, Adsorbed)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Butantan Institute \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Sinovac Biotech"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Expanded Collaboration","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"Jubilant Generics","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jubilant Generics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jubilant Generics \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Jubilant Generics \/ Novavax"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Novavax"},{"orgOrder":0,"company":"Mabion SA","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mabion SA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabion SA \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Mabion SA \/ Novavax"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Oxford \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"University of Oxford \/ Novavax"},{"orgOrder":0,"company":"Simtra BioPharma Solutions","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"COVID-19 Vaccine, Adjuvanted","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Simtra BioPharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Simtra BioPharma Solutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Simtra BioPharma Solutions \/ Novavax"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COVID-19 Vaccine, Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Medicago","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Medicago \/ GSK"},{"orgOrder":0,"company":"Pfenex","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CRM197","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfenex \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Pfenex \/ Serum Institute of India"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CT-P63","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CT-P63","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"CVnCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ German Federal Ministry of Education and Research","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"CVnCoV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"Pulmonem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dapsone","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University Health Centre Research Institute \/ Pulmonem","highestDevelopmentStatusID":"10","companyTruncated":"McGill University Health Centre Research Institute \/ Pulmonem"},{"orgOrder":0,"company":"PharmaDiall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dimolegin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaDiall","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaDiall \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"PharmaDiall \/ Undisclosed"},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"Yunnan Provincial Center for Disease Control and Prevention | Shaanxi Provincial Center for Disease Control and Prevention | Guizhou Provincial Center for Disease Control and Prevention | Shandong Provincial Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DTacP Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changchun BCHT Biotechnology \/ Yunnan Provincial Center for Disease Control and Prevention | Shaanxi Provincial Center for Disease Control and Prevention | Guizhou Provincial Center for Disease Control and Prevention | Shandong Provincial Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Changchun BCHT Biotechnology \/ Yunnan Provincial Center for Disease Control and Prevention | Shaanxi Provincial Center for Disease Control and Prevention | Guizhou Provincial Center for Disease Control and Prevention | Shandong Provincial Center for Disease Control and Prevention"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd."},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"DTwP-HepB-Hib-IPV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DTwP-HepB-IPV-Hib Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DWJ1248","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"DWJ1248","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daewoong Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewoong Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Daewon Pharm. Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"DWKH","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daewon Pharm. Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daewon Pharm. Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daewon Pharm. Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Universit\u00e4tsklinikum Hamburg-Eppendorf","sponsor":"Bernhard Nocht Institute for Tropical Medicine | Goethe University | German Federal Ministry of Education and Research | Monipol Deutschland","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Ebola Zaire Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Universit\u00e4tsklinikum Hamburg-Eppendorf","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Bernhard Nocht Institute for Tropical Medicine | Goethe University | German Federal Ministry of Education and Research | Monipol Deutschland","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4tsklinikum Hamburg-Eppendorf \/ Bernhard Nocht Institute for Tropical Medicine | Goethe University | German Federal Ministry of Education and Research | Monipol Deutschland"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efbemalenograstim Alpha","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Enimmune Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Enterovirus Type 71 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Enimmune Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enimmune Corporation \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Enimmune Corporation \/ Undisclosed"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"Alliance for International Medical Action | Centre de Recherche et de Formation en Infectiologie de Guin\u00e9e | M\u00e9decins Sans Fronti\u00e8res Netherlands | Barcelona Institute for Global Health | University of Bordeaux | INSERM UMR S1136 | Agence Nationale de S\u00e9c","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Ervebo","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANRS, Emerging Infectious Diseases \/ Alliance for International Medical Action | Centre de Recherche et de Formation en Infectiologie de Guin\u00e9e | M\u00e9decins Sans Fronti\u00e8res Netherlands | Barcelona Institute for Global Health | University of Bordeaux | INSERM UMR S1136 | Agence Nationale de S\u00e9c","highestDevelopmentStatusID":"10","companyTruncated":"ANRS, Emerging Infectious Diseases \/ Alliance for International Medical Action | Centre de Recherche et de Formation en Infectiologie de Guin\u00e9e | M\u00e9decins Sans Fronti\u00e8res Netherlands | Barcelona Institute for Global Health | University of Bordeaux | INSERM UMR S1136 | Agence Nationale de S\u00e9c"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Korea Institute of Science and Technology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"EuBiologics \/ Korea Institute of Science and Technology","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Korea Institute of Science and Technology"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"POP Biotechnologies","sponsor":"EuBiologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"EuCorVac-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"POP Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"POP Biotechnologies \/ EuBiologics","highestDevelopmentStatusID":"10","companyTruncated":"POP Biotechnologies \/ EuBiologics"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"EVO100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"ExPEC9V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Extraintestinal Pathogenic E. Coli Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Extraintestinal Pathogenic E. Coli Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Biomedica Foscama","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Glutathione Sodium","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomedica Foscama","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomedica Foscama \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biomedica Foscama \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GP681","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GP681","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GP681","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GP681","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GP681","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Qingfeng Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GP681","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Qingfeng Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Qingfeng Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qingfeng Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Genrix Biopharmaceutical Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GR1801","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Genrix Biopharmaceutical Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Genrix Biopharmaceutical Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GSK3888550A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GSK3888550A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GSK4353001A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Sanofi"},{"orgOrder":0,"company":"Fujian Akeylink Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GST-HG141","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujian Akeylink Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Akeylink Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Akeylink Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Akeylink Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GST-HG141","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujian Akeylink Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujian Akeylink Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fujian Akeylink Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hemagglutinin Protein Nanoparticle Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Hepatitis B (Recombinant) Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hepatitis B Vaccine Recombinant, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies","highestDevelopmentStatusID":"10","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Dynavax Technologies"},{"orgOrder":0,"company":"Huahui Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HH-120","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Huahui Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Huahui Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huahui Health \/ Undisclosed"},{"orgOrder":0,"company":"Huahui Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HH-120","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Huahui Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Huahui Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huahui Health \/ Undisclosed"},{"orgOrder":0,"company":"Huahui Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HH-120","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Huahui Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Huahui Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huahui Health \/ Undisclosed"},{"orgOrder":0,"company":"Huahui Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HH-120","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Huahui Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Huahui Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huahui Health \/ Undisclosed"},{"orgOrder":0,"company":"Huahui Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HH-120","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Huahui Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huahui Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Huahui Health \/ Undisclosed"},{"orgOrder":0,"company":"StemCyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"HPC Cord Blood","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"StemCyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"StemCyte \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HRS-8427","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HRS-8427","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Warsaw","sponsor":"Human Biome Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Human Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medical University of Warsaw","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medical University of Warsaw \/ Human Biome Institute","highestDevelopmentStatusID":"10","companyTruncated":"Medical University of Warsaw \/ Human Biome Institute"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Human Interferon Alpha 1b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"National Vaccine and Serum Institute China","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Human Norovirus Bivalent Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Vaccine and Serum Institute China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Vaccine and Serum Institute China \/ Lanzhou Institute of Biological Products Co., Ltd","highestDevelopmentStatusID":"10","companyTruncated":"National Vaccine and Serum Institute China \/ Lanzhou Institute of Biological Products Co., Ltd"},{"orgOrder":0,"company":"National Vaccine and Serum Institute China","sponsor":"Chengdu Institute of Biological Products Co.,Ltd. | Simoon Record Pharma Information Consulting Co., Ltd. | Beijing Kantorico Statistical Technology | Guangxi Center for Disease Control and Prevention | Hunan Provincial Center for Disease Control and Prev","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus 11-valent Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Vaccine and Serum Institute China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Vaccine and Serum Institute China \/ Chengdu Institute of Biological Products Co.,Ltd. | Simoon Record Pharma Information Consulting Co., Ltd. | Beijing Kantorico Statistical Technology | Guangxi Center for Disease Control and Prevention | Hunan Provincial Center for Disease Control and Prev","highestDevelopmentStatusID":"10","companyTruncated":"National Vaccine and Serum Institute China \/ Chengdu Institute of Biological Products Co.,Ltd. | Simoon Record Pharma Information Consulting Co., Ltd. | Beijing Kantorico Statistical Technology | Guangxi Center for Disease Control and Prevention | Hunan Provincial Center for Disease Control and Prev"},{"orgOrder":0,"company":"Shanghai Bovax Biotechnology Co., Ltd.","sponsor":"Chongqing Bovax Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Bovax Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Bovax Biotechnology Co., Ltd. \/ Chongqing Bovax Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Bovax Biotechnology Co., Ltd. \/ Chongqing Bovax Biopharmaceutical"},{"orgOrder":0,"company":"Beijing Health Guard Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus Nonvalent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Health Guard Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Health Guard Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Health Guard Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Health Guard Biotechnology","sponsor":"Yunnan Center for Disease Control and Prevention | Mile City Center for Disease Control and Prevention | Qiubei County CDC | Yanshan County Center for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Shanghai Stem Ph","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus Nonvalent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Health Guard Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Beijing Health Guard Biotechnology \/ Yunnan Center for Disease Control and Prevention | Mile City Center for Disease Control and Prevention | Qiubei County CDC | Yanshan County Center for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Shanghai Stem Ph","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Health Guard Biotechnology \/ Yunnan Center for Disease Control and Prevention | Mile City Center for Disease Control and Prevention | Qiubei County CDC | Yanshan County Center for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Shanghai Stem Ph"},{"orgOrder":0,"company":"Beijing Health Guard Biotechnology","sponsor":"Jiangsu Province Centers for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Nanjing Sangruisi pharmtech | Shanghai Canming pharmtech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Human Papillomavirus Nonvalent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Health Guard Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Beijing Health Guard Biotechnology \/ Jiangsu Province Centers for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Nanjing Sangruisi pharmtech | Shanghai Canming pharmtech Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Health Guard Biotechnology \/ Jiangsu Province Centers for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Nanjing Sangruisi pharmtech | Shanghai Canming pharmtech Ltd."},{"orgOrder":0,"company":"Beijing Health Guard Biotechnology","sponsor":"Jiangsu Province Centers for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Nanjing Sangruisi Pharmaceutical Technology | School of Public Health, Southeastern University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Human Papillomavirus Nonvalent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Health Guard Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Beijing Health Guard Biotechnology \/ Jiangsu Province Centers for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Nanjing Sangruisi Pharmaceutical Technology | School of Public Health, Southeastern University","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Health Guard Biotechnology \/ Jiangsu Province Centers for Disease Control and Prevention | National Institutes for Food and Drug Control, China | Nanjing Sangruisi Pharmaceutical Technology | School of Public Health, Southeastern University"},{"orgOrder":0,"company":"National Vaccine and Serum Institute China","sponsor":"Chengdu Institute of Biological Products Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Human Papillomavirus Quadrivalent Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Vaccine and Serum Institute China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"National Vaccine and Serum Institute China \/ Chengdu Institute of Biological Products Co.,Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"National Vaccine and Serum Institute China \/ Chengdu Institute of Biological Products Co.,Ltd."},{"orgOrder":0,"company":"International Agency for Research on Cancer","sponsor":"University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Agency for Research on Cancer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Agency for Research on Cancer \/ University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer","highestDevelopmentStatusID":"10","companyTruncated":"International Agency for Research on Cancer \/ University of New Mexico | University of Stellenbosch | University of KwaZulu | Coptic Hope Center | Gabrail Cancer Center Research | Ministry of Health, Swaziland | Baylor College of Medicine Children's Foundation | Sefako Makgatho Health Sciences Univer"},{"orgOrder":0,"company":"Beijing Health Guard Biotechnology","sponsor":"University of Muhammadiyah Malang Hospital | Dr. M Djamil Hospital, Padang","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine, Nonavalent","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Health Guard Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beijing Health Guard Biotechnology \/ University of Muhammadiyah Malang Hospital | Dr. M Djamil Hospital, Padang","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Health Guard Biotechnology \/ University of Muhammadiyah Malang Hospital | Dr. M Djamil Hospital, Padang"},{"orgOrder":0,"company":"Ningbo Rongan Biological Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Human Rabies Vaccine (Human Diploid Cell)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ningbo Rongan Biological Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ningbo Rongan Biological Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ningbo Rongan Biological Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Rongan Biological Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Human Rabies Vaccine (Human Diploid Cell)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ningbo Rongan Biological Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ningbo Rongan Biological Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ningbo Rongan Biological Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Da Vinci Clinic | HGC Rijswijk","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Hyperbaric Oxygen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Da Vinci Clinic | HGC Rijswijk","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Da Vinci Clinic | HGC Rijswijk"},{"orgOrder":0,"company":"Grifols International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Hyperimmune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ National Institutes of Health"},{"orgOrder":0,"company":"Grifols International","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ National Institutes of Health"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ National Institutes of Health"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Hz\/Su Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Hz\/Su Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Immodulon Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IMM-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Immodulon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immodulon Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Immodulon Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biopharma Plasma","sponsor":"Lviv National Medical University | Vinnitsa National Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Immunoglobulins||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biopharma Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biopharma Plasma \/ Lviv National Medical University | Vinnitsa National Medical University","highestDevelopmentStatusID":"10","companyTruncated":"Biopharma Plasma \/ Lviv National Medical University | Vinnitsa National Medical University"},{"orgOrder":0,"company":"University of Health Sciences Lahore","sponsor":"University of Lahore | Amson Vaccine and Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PAKISTAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Health Sciences Lahore","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Health Sciences Lahore \/ University of Lahore | Amson Vaccine and Pharma","highestDevelopmentStatusID":"10","companyTruncated":"University of Health Sciences Lahore \/ University of Lahore | Amson Vaccine and Pharma"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine (Omicron Variant)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated COVID-19 Vaccine (Omicron Variant)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Inactivated Quadrivalent Influenza Vaccine (Split Virion)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inactivated Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"INO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"INO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INO \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"INO \/ Undisclosed"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Inactivated Vero Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Butantan Institute \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Soetomo General Hospital","sponsor":"Indonesia Ministry of Health | Universitas Airlangga | PT Biotis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inavac Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Soetomo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | PT Biotis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | PT Biotis Pharmaceuticals"},{"orgOrder":0,"company":"Dr. Soetomo General Hospital","sponsor":"Universitas Airlangga | Bioxis Pharmaceuticalls | Indonesia Ministry of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inavac Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Soetomo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Soetomo General Hospital \/ Universitas Airlangga | Bioxis Pharmaceuticalls | Indonesia Ministry of Health","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Soetomo General Hospital \/ Universitas Airlangga | Bioxis Pharmaceuticalls | Indonesia Ministry of Health"},{"orgOrder":0,"company":"Dr. Soetomo General Hospital","sponsor":"Indonesia Ministry of Health | Universitas Airlangga | PT Biotis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inavac Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dr. Soetomo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | PT Biotis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Soetomo General Hospital \/ Indonesia Ministry of Health | Universitas Airlangga | PT Biotis Pharmaceuticals"},{"orgOrder":0,"company":"Petrovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Influenza Quadrivalent Inactivated Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Petrovax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Cerus Corporation","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Intercept Treated Red Blood Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cerus Corporation","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Cerus Corporation \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Cerus Corporation \/ BARDA"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Intranasal Influenza Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"J07AX","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sandoz B2B \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"JNJ-78901563","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"JNJ-78901563","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Sanofi"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"JNJ-78901563","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"K-237","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Elanco","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"KIND-030","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kindred Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Kindred Biosciences \/ Elanco","highestDevelopmentStatusID":"10","companyTruncated":"Kindred Biosciences \/ Elanco"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Kirin Holdings Company, Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"LC-Plasma","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"RDC Clinical \/ Kirin Holdings Company, Limited","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Kirin Holdings Company, Limited"},{"orgOrder":0,"company":"National Vaccine and Serum Institute China","sponsor":"China National Biotec Group | Lanzhou Institute of Biological Products Co., Ltd | Beijing Institute of Biological Products Co Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LIBP Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Vaccine and Serum Institute China","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Vaccine and Serum Institute China \/ China National Biotec Group | Lanzhou Institute of Biological Products Co., Ltd | Beijing Institute of Biological Products Co Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"National Vaccine and Serum Institute China \/ China National Biotec Group | Lanzhou Institute of Biological Products Co., Ltd | Beijing Institute of Biological Products Co Ltd."},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"He Bei province Center for Disease control and prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Live Attenuated Influenza Vaccine","moa":"Cell mediated immunity response (CMIR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changchun BCHT Biotechnology \/ He Bei province Center for Disease control and prevention","highestDevelopmentStatusID":"10","companyTruncated":"Changchun BCHT Biotechnology \/ He Bei province Center for Disease control and prevention"},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"He Bei province Center for Disease control and prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Live Attenuated Influenza Vaccine","moa":"Cell mediated immunity response (CMIR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changchun BCHT Biotechnology \/ He Bei province Center for Disease control and prevention","highestDevelopmentStatusID":"10","companyTruncated":"Changchun BCHT Biotechnology \/ He Bei province Center for Disease control and prevention"},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"Hubei Provincial Center for Disease Control and Prevention | Center for Disease Control and Prevention, Fujian | Zhejiang Provincial CDC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Live Attenuated Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Changchun BCHT Biotechnology \/ Hubei Provincial Center for Disease Control and Prevention | Center for Disease Control and Prevention, Fujian | Zhejiang Provincial CDC","highestDevelopmentStatusID":"10","companyTruncated":"Changchun BCHT Biotechnology \/ Hubei Provincial Center for Disease Control and Prevention | Center for Disease Control and Prevention, Fujian | Zhejiang Provincial CDC"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Live Attenuated Mumps Vaccines","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Institute of Biological Products","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Live Attenuated Varicella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Institute of Biological Products \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Institute of Biological Products \/ Undisclosed"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd. | Jiangsu Province Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Live Attenuated Varicella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Jiangsu Province Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Jiangsu Province Center for Disease Control and Prevention"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd. | Jiangsu Province Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Live Attenuated Varicella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Jiangsu Province Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Jiangsu Province Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Changchun BCHT Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Live Attenuated Zoster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Changchun BCHT Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Changchun BCHT Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Changchun BCHT Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LVRNA009","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AIM Vaccine \/ Undisclosed"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"LVRNA009","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"AIM Vaccine \/ AIM Innovation Biotechnology | Ningbo Rongan Biological Pharmaceutical | LiveRNA Therapeutics"},{"orgOrder":0,"company":"AIM Vaccine","sponsor":"LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LVRNA021","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AIM Vaccine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AIM Vaccine \/ LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"AIM Vaccine \/ LiveRNA Therapeutics | Ningbo Rongan Biological Pharmaceutical"},{"orgOrder":0,"company":"Patronus Biotech","sponsor":"Yantai Patronus Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Patronus Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd."},{"orgOrder":0,"company":"Patronus Biotech","sponsor":"Yantai Patronus Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Patronus Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd."},{"orgOrder":0,"company":"Patronus Biotech","sponsor":"Yantai Patronus Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Patronus Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd."},{"orgOrder":0,"company":"Patronus Biotech","sponsor":"Yantai Patronus Biotech Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Patronus Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd."},{"orgOrder":0,"company":"Patronus Biotech","sponsor":"Yantai Patronus Biotech Co., Ltd. | Af?liated Hospital of North Sichuan Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Patronus Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd. | Af?liated Hospital of North Sichuan Medical College","highestDevelopmentStatusID":"10","companyTruncated":"Patronus Biotech \/ Yantai Patronus Biotech Co., Ltd. | Af?liated Hospital of North Sichuan Medical College"},{"orgOrder":0,"company":"Mikrobiomik Healthcare Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MBK-01","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mikrobiomik Healthcare Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mikrobiomik Healthcare Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mikrobiomik Healthcare Company \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Measles And Rubella Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Zydus Lifesciences","highestDevelopmentStatusID":"10","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Shanghai Institute of Biological Products","sponsor":"Victoria Biomedical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Measles, Mumps And Rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Institute of Biological Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Institute of Biological Products \/ Victoria Biomedical Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Institute of Biological Products \/ Victoria Biomedical Research Institute"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"COVID-19 Therapeutics Accelerator","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Measles, Mumps And Rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ COVID-19 Therapeutics Accelerator","highestDevelopmentStatusID":"10","companyTruncated":"Washington University School of Medicine \/ COVID-19 Therapeutics Accelerator"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Men ABCWY Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"MenACYW Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Petrovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Petrovax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Meningococcal (Groups A, C, Y, and W-135) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal B Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Meningococcal B Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Meningococcal B Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Meningococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Meningococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"MG1111","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MK-8527","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MMH-407","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MMH-407","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"University of Zurich","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MMR vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Zurich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Zurich \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Zurich \/ Merck & Co"},{"orgOrder":0,"company":"Pharma VAM","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Molixan","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharma VAM","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharma VAM \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharma VAM \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Daiichi Sankyo \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Daiichi Sankyo \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1010","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1083","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1273.815","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1283.222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1403","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1647","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-based Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Jean-Pierre Van geertruyden","sponsor":"Ace Africa | PENTA Foundation | Bavarian Nordic | European & Developing Countries Clinical Trials Partnership | Universit\u00e9 de Kinshasa | CEPI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jean-Pierre Van geertruyden","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jean-Pierre Van geertruyden \/ Ace Africa | PENTA Foundation | Bavarian Nordic | European & Developing Countries Clinical Trials Partnership | Universit\u00e9 de Kinshasa | CEPI","highestDevelopmentStatusID":"10","companyTruncated":"Jean-Pierre Van geertruyden \/ Ace Africa | PENTA Foundation | Bavarian Nordic | European & Developing Countries Clinical Trials Partnership | Universit\u00e9 de Kinshasa | CEPI"},{"orgOrder":0,"company":"Jean-Pierre Van geertruyden","sponsor":"PENTA Foundation | Ace Africa | European & Developing Countries Clinical Trials Partnership | Bavarian Nordic | Universit\u00e9 de Kinshasa","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"MVA-BN","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jean-Pierre Van geertruyden","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jean-Pierre Van geertruyden \/ PENTA Foundation | Ace Africa | European & Developing Countries Clinical Trials Partnership | Bavarian Nordic | Universit\u00e9 de Kinshasa","highestDevelopmentStatusID":"10","companyTruncated":"Jean-Pierre Van geertruyden \/ PENTA Foundation | Ace Africa | European & Developing Countries Clinical Trials Partnership | Bavarian Nordic | Universit\u00e9 de Kinshasa"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"MVA-BN Filo Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Bavarian Nordic \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ GSK"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN RSV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bavarian Nordic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"MVA-BN-RSV Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bavarian Nordic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bavarian Nordic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bavarian Nordic \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Biofabri","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bharat Biotech \/ Biofabri","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Biofabri"},{"orgOrder":0,"company":"Biofabri","sponsor":"TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Live-Attenuated Tuberculosis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ TuBerculosis Vaccine Initiative | University of Cape Town | Institut Pasteur de Madagascar | Biomedical Research Center EPLS | Universidad de Zaragoza | University of Stellenbosch | University of KwaZulu | Wits Health Consortium"},{"orgOrder":0,"company":"Biofabri","sponsor":"Bharat Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2022","type":"Partnership","leadProduct":"BCG Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ Bharat Biotech"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2023","type":"Agreement","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"Zendal","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Zendal","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zendal \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Zendal \/ IAVI"},{"orgOrder":0,"company":"Biofabri","sponsor":"IAVI","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biofabri","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biofabri \/ IAVI","highestDevelopmentStatusID":"10","companyTruncated":"Biofabri \/ IAVI"},{"orgOrder":0,"company":"IAVI","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.059999999999999998,"dosageForm":"Injection","sponsorNew":"IAVI \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"IAVI","sponsor":"German Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Mycobacterium Tuberculosis Vaccine, Live Attenuated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IAVI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"IAVI \/ German Government","highestDevelopmentStatusID":"10","companyTruncated":"IAVI \/ German Government"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Mycobacterium w","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cadila Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"General Administration of Military Health, Tunisia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TUNISIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NANOS1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"General Administration of Military Health, Tunisia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"General Administration of Military Health, Tunisia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"General Administration of Military Health, Tunisia \/ Undisclosed"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NLP21","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaLead Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Undisclosed"},{"orgOrder":0,"company":"China Medical University Hospital","sponsor":"Tian-I Pharmaceutical,. Co. Ltd. | China Medical University, China | Qualitix Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NRICM101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China Medical University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"China Medical University Hospital \/ Tian-I Pharmaceutical,. Co. Ltd. | China Medical University, China | Qualitix Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"China Medical University Hospital \/ Tian-I Pharmaceutical,. Co. Ltd. | China Medical University, China | Qualitix Clinical Research"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NVX-CoV2515","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NVX-CoV2601","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd. | Hunan Provincial Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Omicron COVID-19 Vaccine (Vero Cell), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Hunan Provincial Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Hunan Provincial Center for Disease Control and Prevention"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd. | Shulan (Hangzhou) Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Omicron COVID-19 Vaccine (Vero Cell), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Shulan (Hangzhou) Hospital","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Shulan (Hangzhou) Hospital"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd. | Wuhan Institute of Biological Products | University of Hong Kong","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Omicron Inactivated COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Wuhan Institute of Biological Products | University of Hong Kong","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd. | Wuhan Institute of Biological Products | University of Hong Kong"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Omicron-Delta Recombinant Protein COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Oral Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"PCV21 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"SK Bioscience \/ Sanofi"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PCV-Free Rotavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Pharm Aid LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pentavalent Live Attenuated Rotavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm Aid LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharm Aid LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharm Aid LLC \/ Undisclosed"},{"orgOrder":0,"company":"Pharm Aid LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pentavalent Live Attenuated Rotavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharm Aid LLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharm Aid LLC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pharm Aid LLC \/ Undisclosed"},{"orgOrder":0,"company":"BioNet-Asia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Pertussis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BioNet-Asia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNet-Asia \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioNet-Asia \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PF-06425090","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PF-06482077","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PF-06482077","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-06928316","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-06928316","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PF-06947386","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-07915234","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PF-07915234","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Hipra Scientific","sponsor":"Veristat | Asphalion | Fundaci\u00f3n FLS | Institut d'Investigacions Biom\u00e8diques","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PHH1-V","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hipra Scientific","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hipra Scientific \/ Veristat | Asphalion | Fundaci\u00f3n FLS | Institut d'Investigacions Biom\u00e8diques","highestDevelopmentStatusID":"10","companyTruncated":"Hipra Scientific \/ Veristat | Asphalion | Fundaci\u00f3n FLS | Institut d'Investigacions Biom\u00e8diques"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pika Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Tergene Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Pneumococcal 15-Valent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tergene Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tergene Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tergene Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Pneumococcal 15-valent\u2013DTaP Combined Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Pneumococcal 21-valent Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Pneumococcal 23-valent Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Aimei Vacin BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Pneumococcal 23-valent Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Aimei Vacin BioPharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aimei Vacin BioPharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Aimei Vacin BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Minhai Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Pneumococcal Polysaccharide Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Minhai Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Minhai Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Minhai Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Fidec Corporation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Poliomyelitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fidec Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fidec Corporation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Fidec Corporation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamilton Health Sciences \/ McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University | Ontario Clinical Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Povidone Iodine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hamilton Health Sciences \/ McMaster University | Ontario Clinical Oncology Group","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ McMaster University | Ontario Clinical Oncology Group"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Prospekta","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Protein-Based COVID-19 Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Protein-Based COVID-19 Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Sanofi","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Protein-Based COVID-19 Vaccine Recombinant, Adjuvant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ GSK"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID19-B","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PTX-COVID19-B","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Everest Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"CDMRP","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Alhydrogel","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ CDMRP","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ CDMRP"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Undisclosed"},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"Malaria Research and Training Center, Mali International Center of Excellence in Research, University of Sciences, Techniques, and Technologies of Bamako, Mali | KEMRI Centre for Global Health Research, Kisumu, Kenya | Clinical Research Unit of Nanoro, In","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Pyronaridine-artesunate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Liverpool School of Tropical Medicine \/ Malaria Research and Training Center, Mali International Center of Excellence in Research, University of Sciences, Techniques, and Technologies of Bamako, Mali | KEMRI Centre for Global Health Research, Kisumu, Kenya | Clinical Research Unit of Nanoro, In","highestDevelopmentStatusID":"10","companyTruncated":"Liverpool School of Tropical Medicine \/ Malaria Research and Training Center, Mali International Center of Excellence in Research, University of Sciences, Techniques, and Technologies of Bamako, Mali | KEMRI Centre for Global Health Research, Kisumu, Kenya | Clinical Research Unit of Nanoro, In"},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Groupe de Recherche Action en Sante | Centres for Disease Control and Prevention, Kenya. | Bill & Melinda Gates Foundation | Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Pyronaridine-artesunate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liverpool School of Tropical Medicine \/ London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Groupe de Recherche Action en Sante | Centres for Disease Control and Prevention, Kenya. | Bill & Melinda Gates Foundation | Centers for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Liverpool School of Tropical Medicine \/ London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Groupe de Recherche Action en Sante | Centres for Disease Control and Prevention, Kenya. | Bill & Melinda Gates Foundation | Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus (Serotypes 6, 11, 16 and 18) Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Shanghai Bovax Biotechnology Co., Ltd.","sponsor":"Chongqing Bovax Biopharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Human Papillomavirus Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Bovax Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Bovax Biotechnology Co., Ltd. \/ Chongqing Bovax Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Bovax Biotechnology Co., Ltd. \/ Chongqing Bovax Biopharmaceutical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Inactivated Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Modrna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"COVID-19 mRNA Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine (Split Virion), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine (Split Virion, Inactivated)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine (Split Virus)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M Vaccine, Adjuvanted","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emergent BioSolutions \/ Novavax","highestDevelopmentStatusID":"10","companyTruncated":"Emergent BioSolutions \/ Novavax"},{"orgOrder":0,"company":"Ab&B Bio-tech","sponsor":"Henan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Virus Subunit Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ab&B Bio-tech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ab&B Bio-tech \/ Henan Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Ab&B Bio-tech \/ Henan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Quadrivalent Recombinant Norovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Seasonal Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Quadrivalent Seasonal Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Matrix-M","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ University of Oxford","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ University of Oxford"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Sponsor GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Sponsor GmbH"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Rabies Vaccine (Serum-free Vero Cell), Freeze-dried","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Rabies Vaccine (Serum-free Vero Cell), Freeze-dried","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"LakeShore Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Rabies Vaccine, PIKA Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"LakeShore Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LakeShore Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"LakeShore Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Virus-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Radamine Viro","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Raphamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Raphamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Raphamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Raphamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Materia Medica Holding","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Raphamin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Materia Medica Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Materia Medica Holding \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Materia Medica Holding \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RAY1216","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RAY1216","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Rebiotix"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Rebiotix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Ferring Pharmaceuticals \/ Rebiotix","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Rebiotix"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ferring Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ferring Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Undisclosed"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Undisclosed"},{"orgOrder":0,"company":"Rebiotix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Rbx2660","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Rebiotix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Rebiotix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Rebiotix \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"WestVac Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Trimer Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WestVac Biopharma \/ WestVac Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ WestVac Biopharma"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Trivalent Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WestVac Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"West China Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ West China Hospital","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ West China Hospital"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"West China Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ West China Hospital","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ West China Hospital"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"WestVac Biopharma","sponsor":"West China Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"WestVac Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"WestVac Biopharma \/ West China Hospital","highestDevelopmentStatusID":"10","companyTruncated":"WestVac Biopharma \/ West China Hospital"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Beijing Institute of Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CanSino Biologics \/ Beijing Institute of Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Beijing Institute of Biotechnology"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Beijing Institute of Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CanSino Biologics \/ Beijing Institute of Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Beijing Institute of Biotechnology"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Beijing Institute of Biotechnology | Jiangsu Province Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"CanSino Biologics \/ Beijing Institute of Biotechnology | Jiangsu Province Centers for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Beijing Institute of Biotechnology | Jiangsu Province Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Beijing Institute of Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Beijing Institute of Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Beijing Institute of Biotechnology"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Beijing Institute of Biotechnology | Jiangsu Province Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Beijing Institute of Biotechnology | Jiangsu Province Centers for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Beijing Institute of Biotechnology | Jiangsu Province Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Beijing Institute of Biotechnology | Canadian Center for Vaccinology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Beijing Institute of Biotechnology | Canadian Center for Vaccinology","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Beijing Institute of Biotechnology | Canadian Center for Vaccinology"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Jiangsu Province Centers for Disease Control and Prevention | Hubei Provincial Center for Disease Control and Prevention | Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Jiangsu Province Centers for Disease Control and Prevention | Hubei Provincial Center for Disease Control and Prevention | Tongji Hospital","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China | Jiangsu Province Centers for Disease Control and Prevention | Hubei Provincial Center for Disease Control and Prevention | Tongji Hospital"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CanSino Biologics \/ Jiangsu Province Centers for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Jiangsu Province Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Petrovax","sponsor":"CanSino Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Petrovax \/ CanSino Biologics","highestDevelopmentStatusID":"10","companyTruncated":"Petrovax \/ CanSino Biologics"},{"orgOrder":0,"company":"Beijing Luzhu Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Herpes Zoster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Luzhu Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Beijing Luzhu Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Luzhu Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Human Alkaline Phosphatase","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AM-Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AM-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"recombinant influenza vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"recombinant influenza vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"SPP Pharmaclon Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Interferon gamma-1b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"SPP Pharmaclon Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SPP Pharmaclon Ltd. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SPP Pharmaclon Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinnaGen \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Vaxine"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinnaGen \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Vaxine"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinnaGen \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Vaxine"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Shahid Beheshti University of Medical Sciences | Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant protein-based COVID-19 vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinnaGen \/ Shahid Beheshti University of Medical Sciences | Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Shahid Beheshti University of Medical Sciences | Vaxine"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Advax-SM","moa":"||SARS-CoV-2 S||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinnaGen \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Vaxine"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"qNIV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant SARS-CoV-2 Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant SARS-CoV-2 Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant SARS-CoV-2 Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Guangdong Center for Disease Prevention and Control | Simoon Record Pharma Information Consulting Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant SARS-CoV-2 Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Livzon Pharmaceutical Group \/ Guangdong Center for Disease Prevention and Control | Simoon Record Pharma Information Consulting Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Guangdong Center for Disease Prevention and Control | Simoon Record Pharma Information Consulting Co., Ltd."},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant SARS-CoV-2 Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Livzon Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant SARS-CoV-2 Fusion Protein Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Livzon Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Livzon Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Livzon Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Rec-Biotechnology","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Two-Component COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Rec-Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Rec-Biotechnology \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Rec-Biotechnology \/ IQVIA"},{"orgOrder":0,"company":"Jiangsu Rec-Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Two-Component COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Rec-Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Jiangsu Rec-Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Rec-Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Rec-Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Two-Component COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Rec-Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Jiangsu Rec-Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Rec-Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAXVAX Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Zoster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MAXVAX Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MAXVAX Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MAXVAX Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"MAXVAX Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Zoster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"MAXVAX Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"MAXVAX Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MAXVAX Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"REGN-EB3","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Series E Financing","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ AMR Action Fund","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ AMR Action Fund"},{"orgOrder":0,"company":"TenNor Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rifasutenizol","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TenNor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TenNor Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TenNor Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Rotavirus Vaccine (Live Attenuated, Oral)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bharat Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Rotavirus Vaccine (Live Attenuated, Oral)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Bharat Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Undisclosed"},{"orgOrder":0,"company":"University of Chile","sponsor":"Bharat Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHILE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Rotavirus Vaccine (Live Attenuated, Oral)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Chile","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"University of Chile \/ Bharat Biotech","highestDevelopmentStatusID":"10","companyTruncated":"University of Chile \/ Bharat Biotech"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Georgia Institute for Clinical Research, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Rotavirus Vaccine (Live Attenuated,Oral)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Georgia Institute for Clinical Research, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Bharat Biotech \/ Georgia Institute for Clinical Research, LLC"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Rotavirus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSV 4Mat Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RSV Maternal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSV Maternal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSV Maternal Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"RSVpreF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVpreF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVpreF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVpreF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVpreF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"RSVpreF Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AS01","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 OA vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"RSVPreF3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"RSVPreF3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"RSVPreF3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S. Flexneri\u2013S. Sonnei Bivalent Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"S. Flexneri\u2013S. Sonnei Bivalent Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Zhifei Lvzhu Biopharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S. Flexneri\u2013S. Sonnei Bivalent Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Zhifei Lvzhu Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Zhifei Lvzhu Biopharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S-268019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"S-268019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"S-268019","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"S-268019-b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Intravacc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sabin Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intravacc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Intravacc \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Minhai Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Sabin Inactivated Poliovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Beijing Minhai Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Minhai Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Minhai Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sabin Strain Based Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Intravacc","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sabin Strain Based Inactivated Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Intravacc \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Intravacc \/ Sinovac Biotech"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Vaxine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 recombinant spike protein","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinnaGen \/ Vaxine","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Vaxine"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 rS Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SARS-CoV-2 rS Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Novavax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"China National Biotec Group","sponsor":"Beijing Institute of Biological Products Co Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine (Vero Cell), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"China National Biotec Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"China National Biotec Group \/ Beijing Institute of Biological Products Co Ltd."},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Beijing Minhai Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine (Vero Cell), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Kangtai Biological Products \/ Beijing Minhai Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Kangtai Biological Products \/ Beijing Minhai Biotechnology"},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Beijing Minhai Biotechnology | Hunan Provincial Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine (Vero Cell), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Kangtai Biological Products \/ Beijing Minhai Biotechnology | Hunan Provincial Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Kangtai Biological Products \/ Beijing Minhai Biotechnology | Hunan Provincial Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Shenzhen Kangtai Biological Products","sponsor":"Beijing Minhai Biotechnology | Hunan Provincial Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Vaccine (Vero Cell), Inactivated","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shenzhen Kangtai Biological Products","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shenzhen Kangtai Biological Products \/ Beijing Minhai Biotechnology | Hunan Provincial Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Kangtai Biological Products \/ Beijing Minhai Biotechnology | Hunan Provincial Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Novan","sponsor":"Therapeutics, Inc. | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SB206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Novan","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novan \/ Therapeutics, Inc. | Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Novan \/ Therapeutics, Inc. | Syneos Health"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations | International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Coalition for Epidemic Preparedness Innovations | International Vaccine Institute","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Coalition for Epidemic Preparedness Innovations | International Vaccine Institute"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SCB-2019 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SCB-2023 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"SCB-2023 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clover Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clover Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vietnam Military Medical University","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam | Vietstar Biomedical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vietnam Military Medical University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vietnam Military Medical University \/ Institute of Vaccines and Medical Biologicals, Vietnam | Vietstar Biomedical Research","highestDevelopmentStatusID":"10","companyTruncated":"Vietnam Military Medical University \/ Institute of Vaccines and Medical Biologicals, Vietnam | Vietstar Biomedical Research"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.17999999999999999,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Financing","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0.75,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.75,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHEN26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Kexing Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHEN26","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kexing Biopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kexing Biopharm \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kexing Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SHR-1905","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SHR-1905","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR8008","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"SHR8008","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sii Inactivated Salk Polio Vaccine (Adsorbed)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Sii Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Russian Direct Investment Fund | iPharma | Moscow Government","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Sputnik Light Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Russian Direct Investment Fund | iPharma | Moscow Government","highestDevelopmentStatusID":"10","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Russian Direct Investment Fund | iPharma | Moscow Government"},{"orgOrder":0,"company":"Shanghai Jiatan Pharmatech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sudapyridine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shanghai Jiatan Pharmatech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Jiatan Pharmatech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Jiatan Pharmatech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"TAK-003","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Kirby Institute","sponsor":"Seqirus | Medical Research Future Fund","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Td Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kirby Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kirby Institute \/ Seqirus | Medical Research Future Fund","highestDevelopmentStatusID":"10","companyTruncated":"Kirby Institute \/ Seqirus | Medical Research Future Fund"},{"orgOrder":0,"company":"Sao Thai Duong","sponsor":"Clinical Research Viet Nam Skill Training And Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TD0069","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sao Thai Duong","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sao Thai Duong \/ Clinical Research Viet Nam Skill Training And Consulting","highestDevelopmentStatusID":"10","companyTruncated":"Sao Thai Duong \/ Clinical Research Viet Nam Skill Training And Consulting"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ningbo Rongan Biological Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Test Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ningbo Rongan Biological Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ningbo Rongan Biological Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Ningbo Rongan Biological Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Testofen","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tetanus Vaccine, Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"CanSino Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tetanus Vaccine, Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CanSino Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CanSino Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CanSino Biologics \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Tetanus Vaccine, Adsorbed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"IBSS BIOMED","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"POLAND","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tetanus-Diphtheria Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IBSS BIOMED","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSS BIOMED \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSS BIOMED \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Panacea Biotec Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tetravalent Chimeric Dengue Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Panacea Biotec Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacea Biotec Limited \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Panacea Biotec Limited \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Tetravalent Dengue Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Anhui Zhifei Longcom Biologic Pharmacy","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Tetravalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Anhui Zhifei Longcom Biologic Pharmacy","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Anhui Zhifei Longcom Biologic Pharmacy \/ Undisclosed"},{"orgOrder":0,"company":"Pontificia Universidad Catolica de Chile","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHILE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Tetravalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pontificia Universidad Catolica de Chile","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pontificia Universidad Catolica de Chile \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Pontificia Universidad Catolica de Chile \/ Sinovac Biotech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Tick-Borne Encephalitis Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TQC2731","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TQC2731","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Sinovac Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Trivalent Inactivated COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinovac Biotech \/ Sinovac Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Sinovac Biotech"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine (Split Virion, Inactivated)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine, MF59-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine, MF59-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"International Centre for Diarrhoeal Disease Research, Bangladesh","sponsor":"Zydus Lifesciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BANGLADESH","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Typhoid Vi Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"International Centre for Diarrhoeal Disease Research, Bangladesh","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Zydus Lifesciences","highestDevelopmentStatusID":"10","companyTruncated":"International Centre for Diarrhoeal Disease Research, Bangladesh \/ Zydus Lifesciences"},{"orgOrder":0,"company":"Promomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Tyrosyl-D-Alanyl-Glycyl-Phenylalanyl-Leucyl-Arginine Succinate","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Promomed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Promomed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Promomed \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"V110","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V114","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V114","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V116","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"V181","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"V181","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"V503","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"VAC18193","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Wits Health Consortium","sponsor":"National Department of Health of South Africa | National Institute of Communicable Diseases | KwaZulu-Natal Research Innovation and Sequencing Platform | Fred Hutchinson Cancer Center | Hutchinson Center Research Institute of South Africa | Johnson & John","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Wits Health Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wits Health Consortium \/ National Department of Health of South Africa | National Institute of Communicable Diseases | KwaZulu-Natal Research Innovation and Sequencing Platform | Fred Hutchinson Cancer Center | Hutchinson Center Research Institute of South Africa | Johnson & John","highestDevelopmentStatusID":"10","companyTruncated":"Wits Health Consortium \/ National Department of Health of South Africa | National Institute of Communicable Diseases | KwaZulu-Natal Research Innovation and Sequencing Platform | Fred Hutchinson Cancer Center | Hutchinson Center Research Institute of South Africa | Johnson & John"},{"orgOrder":0,"company":"Hualan Biological Bacterin Co. Ltd.","sponsor":"Henan Center for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hualan Biological Bacterin Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hualan Biological Bacterin Co. Ltd. \/ Henan Center for Disease Control and Prevention","highestDevelopmentStatusID":"10","companyTruncated":"Hualan Biological Bacterin Co. Ltd. \/ Henan Center for Disease Control and Prevention"},{"orgOrder":0,"company":"Suzhou OSAI Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Vaginal L. Crispatus Live Bacteria","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Suzhou OSAI Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Suzhou OSAI Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou OSAI Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Affiliates of Magnetar Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Series D Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Affiliates of Magnetar Capital","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Affiliates of Magnetar Capital"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"AXA IM Alts","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Financing","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.11,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ AXA IM Alts","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ AXA IM Alts"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ BARDA"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"PureTech Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vedanta Biosciences \/ PureTech Health","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ PureTech Health"},{"orgOrder":0,"company":"Vedanta Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"VE303","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vedanta Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedanta Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vedanta Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Vero Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Vero Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"Butantan Institute","sponsor":"Valneva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VLA1553","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Butantan Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Butantan Institute \/ Valneva","highestDevelopmentStatusID":"10","companyTruncated":"Butantan Institute \/ Valneva"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Vakzine Projekt Management","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Vakzine Projekt Management","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Vakzine Projekt Management"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Vakzine Projekt Management","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vakzine Projekt Management","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vakzine Projekt Management \/ FGK Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Vakzine Projekt Management \/ FGK Clinical Research"},{"orgOrder":0,"company":"Vakzine Projekt Management","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vakzine Projekt Management","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vakzine Projekt Management \/ FGK Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Vakzine Projekt Management \/ FGK Clinical Research"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Serum Institute of India | Max Planck Institute for Infection Biology | Verity Pharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"VPM1002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University Health Network, Toronto \/ Serum Institute of India | Max Planck Institute for Infection Biology | Verity Pharmaceuticals Inc","highestDevelopmentStatusID":"10","companyTruncated":"University Health Network, Toronto \/ Serum Institute of India | Max Planck Institute for Infection Biology | Verity Pharmaceuticals Inc"},{"orgOrder":0,"company":"Invivyd","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Novotech"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"VYD222","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"VYD222","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invivyd \/ Novotech","highestDevelopmentStatusID":"10","companyTruncated":"Invivyd \/ Novotech"},{"orgOrder":0,"company":"Biomad","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xagrotin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biomad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomad \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Biomad \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XC221","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"XC221","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"RSV Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"XC221","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RSV Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RSV Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RSV Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"RSV Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"XC221","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RSV Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RSV Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RSV Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Valenta Pharm JSC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Valenta Pharm JSC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valenta Pharm JSC \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Valenta Pharm JSC \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine (Live)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine (Live)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ZSP1273","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Raynovent Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZSP1273","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Raynovent Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Raynovent Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Raynovent Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmaJet","sponsor":"Zydus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"ZyCoV-D","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"PharmaJet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaJet \/ Zydus Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"PharmaJet \/ Zydus Pharmaceuticals"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"L-Lactic Acid","moa":"||Vaginal pH","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Evofem Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Evofem Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Varicella Vaccine","moa":"Varicella-zoster virus gH\/gL","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Varicella Vaccine","moa":"Varicella-zoster virus gH\/gL","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Varicella Vaccine","moa":"Varicella-zoster virus gH\/gL","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Varicella Vaccine","moa":"Varicella-zoster virus gH\/gL","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Angers","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University Hospital, Angers","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Angers \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Angers \/ Viatris"},{"orgOrder":0,"company":"Canadian College of Naturopathic Medicine","sponsor":"Ottawa Hospital Research Institute | Vitazan Professional | New Roots Herbal","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Canadian College of Naturopathic Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Canadian College of Naturopathic Medicine \/ Ottawa Hospital Research Institute | Vitazan Professional | New Roots Herbal","highestDevelopmentStatusID":"10","companyTruncated":"Canadian College of Naturopathic Medicine \/ Ottawa Hospital Research Institute | Vitazan Professional | New Roots Herbal"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"Barts & The London NHS Trust | Pharma Nord | Fischer Family Trust | The AIM Foundation | Synergy Biologics Ltd | Cytoplan Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Queen Mary University of London \/ Barts & The London NHS Trust | Pharma Nord | Fischer Family Trust | The AIM Foundation | Synergy Biologics Ltd | Cytoplan Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Queen Mary University of London \/ Barts & The London NHS Trust | Pharma Nord | Fischer Family Trust | The AIM Foundation | Synergy Biologics Ltd | Cytoplan Ltd"},{"orgOrder":0,"company":"CHU Sainte-Justine","sponsor":"Canadian Institutes of Health Research | Laboratoire Riva","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CHU Sainte-Justine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CHU Sainte-Justine \/ Canadian Institutes of Health Research | Laboratoire Riva","highestDevelopmentStatusID":"10","companyTruncated":"CHU Sainte-Justine \/ Canadian Institutes of Health Research | Laboratoire Riva"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Harvard Medical School (HMS and HSDM) | Harvard School of Public Health (HSPH) | Fenway Health and Beth Israel Deaconess Medical Center | Tishcon Corporation | Takeda Pharmaceutical | Quest Diagnostics-Nichols Insitute | LabCorp | Trialfacts | Karolinska ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Vitamin D","moa":"Vitamin D receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Harvard Medical School (HMS and HSDM) | Harvard School of Public Health (HSPH) | Fenway Health and Beth Israel Deaconess Medical Center | Tishcon Corporation | Takeda Pharmaceutical | Quest Diagnostics-Nichols Insitute | LabCorp | Trialfacts | Karolinska ","highestDevelopmentStatusID":"10","companyTruncated":"Brigham and Women's Hospital \/ Harvard Medical School (HMS and HSDM) | Harvard School of Public Health (HSPH) | Fenway Health and Beth Israel Deaconess Medical Center | Tishcon Corporation | Takeda Pharmaceutical | Quest Diagnostics-Nichols Insitute | LabCorp | Trialfacts | Karolinska "},{"orgOrder":0,"company":"Sinovac Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinovac Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinovac Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sinovac Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"University of Vermont Medical Center | University of Sao Paulo | Hopital Charles Lemoyne | William Osler Health System | Mount Sinai Hospital | Trillium Health Partners | St. Joseph's Health Centre Toronto | The Ottawa Hospital | H\u00f4pital du Sacre-C\u0153ur de ","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ University of Vermont Medical Center | University of Sao Paulo | Hopital Charles Lemoyne | William Osler Health System | Mount Sinai Hospital | Trillium Health Partners | St. Joseph's Health Centre Toronto | The Ottawa Hospital | H\u00f4pital du Sacre-C\u0153ur de ","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ University of Vermont Medical Center | University of Sao Paulo | Hopital Charles Lemoyne | William Osler Health System | Mount Sinai Hospital | Trillium Health Partners | St. Joseph's Health Centre Toronto | The Ottawa Hospital | H\u00f4pital du Sacre-C\u0153ur de "},{"orgOrder":0,"company":"ARJ Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"ARJ Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARJ Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"ARJ Medical \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"BetterLife Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"BetterLife Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"BetterLife Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BetterLife Pharma \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Vir Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Vir Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Vir Biotechnology"},{"orgOrder":0,"company":"Circularity Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Circularity Healthcare","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Circularity Healthcare \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Circularity Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"Unity Health Toronto | University of Vermont Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ Unity Health Toronto | University of Vermont Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ Unity Health Toronto | University of Vermont Medical Center"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Fosmanogepix","moa":"GPI-anchored wall transfer protein 1","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Basilea Pharmaceutica","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Infusion","sponsorNew":"Basilea Pharmaceutica \/ BARDA","highestDevelopmentStatusID":"10","companyTruncated":"Basilea Pharmaceutica \/ BARDA"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human Interferon Alpha-2b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu CoenBiotech","sponsor":"Beijing Chest Hospital, Capital Medical University | Wuhan Pulmonary Hospital | Changsha Central Hospital | The First Affiliated Hospital of Xinxiang Medical College | Liuzhou People's Hospital | Wuhan Central Hospital | Yichang Central People\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Chengdu CoenBiotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chengdu CoenBiotech \/ Beijing Chest Hospital, Capital Medical University | Wuhan Pulmonary Hospital | Changsha Central Hospital | The First Affiliated Hospital of Xinxiang Medical College | Liuzhou People's Hospital | Wuhan Central Hospital | Yichang Central People\u2019s Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu CoenBiotech \/ Beijing Chest Hospital, Capital Medical University | Wuhan Pulmonary Hospital | Changsha Central Hospital | The First Affiliated Hospital of Xinxiang Medical College | Liuzhou People's Hospital | Wuhan Central Hospital | Yichang Central People\u2019s Hospital"},{"orgOrder":0,"company":"Medicines Development for Global Health","sponsor":"Murdoch Childrens Research Institute | Kirby Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Moxidectin","moa":"Gamma-aminobutyric acid receptor (GAR)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medicines Development for Global Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines Development for Global Health \/ Murdoch Childrens Research Institute | Kirby Institute","highestDevelopmentStatusID":"10","companyTruncated":"Medicines Development for Global Health \/ Murdoch Childrens Research Institute | Kirby Institute"},{"orgOrder":0,"company":"Cidara Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"CD388","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cidara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cidara Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Cidara Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University College, London","sponsor":"National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University College, London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University College, London \/ National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M","highestDevelopmentStatusID":"10","companyTruncated":"University College, London \/ National University of Medical Sciences, Pakistan | Aurum Institute | Biomedical Research and Training Institute, Zimbabwe | Foundation for Innovative New Diagnostics, Switzerland | KTH Royal Institute of Technology | London School of Hygiene & Tropical M"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Inactivated EV71 Enterovirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medigen Vaccine Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medigen Vaccine Biologics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medigen Vaccine Biologics \/ Undisclosed"},{"orgOrder":0,"company":"StemCyte","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"HPC Cord Blood","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"StemCyte \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"StemCyte \/ Undisclosed"},{"orgOrder":0,"company":"TCM Biotech International Corp.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"Viral reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"TCM Biotech International Corp.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"TCM Biotech International Corp. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"TCM Biotech International Corp. \/ Undisclosed"}]

    Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : MenACYW Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Quadrivalent Meningococcal Vaccine Safety and Immunogenicity In Healthy Children China

                            Details : MenACYW Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Meningococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 22, 2025

                            Lead Product(s) : MenACYW Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Yellow Fever Vaccine (Live)

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population

                            Details : Yellow Fever Vaccine (live) is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Yellow Fever.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 05, 2025

                            Lead Product(s) : Yellow Fever Vaccine (Live)

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Yellow Fever Vaccine (Live)

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults

                            Details : Yellow Fever Vaccine (live) is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Yellow Fever.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 03, 2025

                            Lead Product(s) : Yellow Fever Vaccine (Live)

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

                            Details : 21-valent Pneumococcal Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pneumococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 16, 2025

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Pneumococcal 21-valent Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine...

                            Details : Pneumococcal 21-valent Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pneumococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : Pneumococcal 21-valent Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participant...

                            Details : Itepekimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinosinusitis with Nasal Polyps.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 19, 2025

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participant...

                            Details : Itepekimab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinosinusitis with Nasal Polyps.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 19, 2025

                            Lead Product(s) : Itepekimab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : ExPEC9V

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi Updates on Extraintestinal Pathogenic E. Coli Vaccine Phase 3 Clinical Study

                            Details : ExPEC9V (9-valent extraintestinal pathogenic escherichia coli vaccine) is being evaluated for invasive extraintestinal pathogenic escherichia coli disease in adults aged 60 years And older.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 17, 2025

                            Lead Product(s) : ExPEC9V

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococ...

                            Details : 21-valent Pneumococcal Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pneumococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Mont...

                            Details : 21-valent Pneumococcal Conjugate Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pneumococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : 21-valent Pneumococcal Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth